ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Doxycycline: Drug information

Doxycycline: Drug information
(For additional information see "Doxycycline: Patient drug information" and see "Doxycycline: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Acticlate [DSC];
  • Avidoxy;
  • Doryx;
  • Doryx MPC;
  • Doxy 100;
  • Lymepak [DSC];
  • Mondoxyne NL;
  • Morgidox [DSC];
  • Okebo [DSC];
  • Oracea;
  • TargaDOX;
  • Vibramycin
Brand Names: Canada
  • APO-Doxy;
  • APO-Doxycycline MR;
  • Apprilon;
  • Doxycin;
  • Doxytab;
  • Periostat;
  • PRZ-Doxycycline;
  • TEVA-Doxycycline
Pharmacologic Category
  • Antibiotic, Tetracycline Derivative
Dosing: Adult

Dosage guidance:

Dosing: Doxycycline is available as hyclate, monohydrate, and calcium salts. All doses are expressed as doxycycline base.

Usual dosage range:

Oral: IR and most ER formulations: 100 to 200 mg/day in 1 to 2 divided doses. Note: 60 mg of modified polymer-coated tablet (Doryx MPC) is equivalent to 50 mg conventional delayed-release tablet and 120 mg of modified polymer-coated tablet (Doryx MPC) is equivalent to 100 mg conventional delayed-release tablet.

IV: 100 mg every 12 hours. Note: IV form may cause phlebitis.

Acne vulgaris, inflammatory, moderate to severe

Acne vulgaris, inflammatory, moderate to severe (off-label dose):

Note: Use in combination with topical acne therapy. Treatment should ideally be limited to 3 to 4 months to minimize the risk of resistance (Ref).

Oral:

Immediate release: 50 to 100 mg twice daily or 100 mg once daily (Ref).

Extended release: 100 mg twice daily on day 1, then 100 mg once daily (Ref).

Subantimicrobial dosing: 20 mg twice daily (immediate release) or 40 mg once daily (delayed release) (Ref).

Actinomycosis

Actinomycosis (alternative agent): Oral, IV: 100 mg every 12 hours. Optimal duration is uncertain; some experts suggest total durations of 2 to 6 months for mild infection and 6 to 12 months (including 4 to 6 weeks of parenteral therapy) for severe or extensive infection (Ref).

Anaplasmosis and ehrlichiosis

Anaplasmosis and ehrlichiosis (off-label use): Oral, IV: 100 mg twice daily for 10 days or at least 3 days after resolution of fever (Ref).

Anthrax

Anthrax: Note: Consult public health officials for event-specific recommendations.

Inhalational (postexposure prophylaxis): Oral: 100 mg every 12 hours; duration depends on anthrax vaccine status and series completion, age, immune status, and pregnancy/breastfeeding status. For those who have not previously received an anthrax vaccine, duration ranges from 42 to 60 days (Ref). Some experts favor longer durations of prophylaxis (eg, total of 3 to 4 months) for patients who are immunocompromised or remain unvaccinated (Ref).

Note: Anthrax vaccine should also be administered to exposed individuals (Ref).

Cutaneous (without systemic involvement), treatment: Oral: 100 mg every 12 hours for 7 to 10 days after naturally acquired infection; treat for 60 days for bioterrorism-related cases. Note: Treat patients with extensive edema or cutaneous lesions of the head or neck with a parenteral regimen recommended for systemic involvement (Ref).

Systemic (meningitis excluded; alternative agent), treatment: IV: Initial: 200 mg as a single dose, then 100 mg every 12 hours, in combination with a bactericidal agent; treat for 2 weeks or until clinically stable, whichever is longer. Note: Antitoxin should also be administered for systemic anthrax. Following a course of IV combination therapy, patients exposed to aerosolized spores require oral doxycycline monotherapy to complete a total antimicrobial course of 60 days (Ref).

Bartonella spp. infection

Bartonella spp. infection:

Patients with HIV:

Treatment: Note: Duration of therapy is ≥3 months; continuation of therapy depends on clinical condition and response to therapy (Ref).

Bacillary angiomatosis, cat scratch disease, peliosis hepatis, bacteremia, and osteomyelitis: Oral, IV: 100 mg every 12 hours (Ref). Note: Some experts use in combination with gentamicin for the first 2 weeks of therapy for patients with Bartonella bacteremia (Ref).

CNS infections: Oral, IV: 100 mg every 12 hours; may use in combination with rifampin (Ref).

Endocarditis: Oral, IV: 100 mg every 12 hours; use in combination with rifampin for the first 6 weeks (or gentamicin for first 2 weeks if rifampin cannot be used) (Ref).

Other severe infections: Oral, IV: 100 mg every 12 hours in combination with rifampin (Ref); some experts initiate with IV therapy and transition to oral when patient becomes clinically stable (Ref).

Suppressive therapy: Note: For patients who experience a relapse after receiving a ≥3-month course of primary treatment.

Oral: 100 mg every 12 hours. Continue until patient has received ≥3 months of therapy and CD4 count is >200 cells/mm3 for ≥6 months; some experts discontinue therapy only if Bartonella titers have also decreased 4-fold (Ref).

Patients without HIV:

Bacteremia without endocarditis: Oral: 200 mg once daily or 100 mg twice daily for 4 weeks with gentamicin (or rifampin if gentamicin cannot be used) for first 2 weeks (Ref).

Cat scratch disease, CNS infection, and neuroretinitis: Oral, IV: 100 mg twice daily in combination with rifampin (Ref).

Endocarditis: Oral, IV: 100 mg every 12 hours for 3 months; use in combination with rifampin for the first 6 weeks (or gentamicin for first 2 weeks if rifampin cannot be used) (Ref).

Bite wound infection, prophylaxis or treatment

Bite wound infection, prophylaxis or treatment (animal or human bite) (alternative agent) (off-label use): Oral, IV: 100 mg twice daily in combination with an appropriate agent for anaerobes. Duration is 3 to 5 days for prophylaxis; for established infection, continue for 1 to 2 days after resolution, typically 5 to 14 days total, although deep or complicated infections may require a longer duration (Ref).

Brucellosis

Brucellosis:

Treatment:

Endocarditis or neurobrucellosis: Limited data available: IV, Oral: 100 mg twice daily for at least 12 weeks (may be needed for up to 6 months); use as part of an appropriate combination regimen (Ref).

Uncomplicated (nonfocal): Oral: 100 mg twice daily for 6 weeks as part of an appropriate combination regimen (Ref).

Spondylitis: Oral: 100 mg twice daily for at least 12 weeks as part of an appropriate combination regimen (Ref).

Postexposure prophylaxis (high-risk laboratory exposure): Oral: 100 mg twice daily with rifampin for 3 weeks (Ref); for exposure to B. abortus RB51 strains, some experts give doxycycline plus trimethoprim-sulfamethoxazole (Ref).

Bullous pemphigoid

Bullous pemphigoid (off-label use): Oral: 100 mg twice daily, in combination with topical or systemic corticosteroids (EADV [Borradori 2022]; Williams 2017).

Cholera, treatment

Cholera (Vibrio cholerae), treatment (adjunctive agent): Note: For use in combination with rehydration therapy in patients with moderate to severe volume depletion. Due to resistance concerns, antimicrobial therapy during an outbreak or epidemic should be guided by isolate susceptibility (Ref).

Oral: 300 mg as a single dose (Ref).

Chronic obstructive pulmonary disease, acute exacerbation

Chronic obstructive pulmonary disease, acute exacerbation (off-label use): Oral: 100 mg once or twice daily for 5 to 7 days (Ref). Note: Some experts reserve for patients with uncomplicated COPD (eg, <65 years of age without major comorbidities, FEV1 >50% predicted, infrequent exacerbations) (Ref).

Endocarditis, prophylaxis before invasive dental procedures

Endocarditis, prophylaxis before invasive dental procedures (alternative agent for patients with penicillin allergy) (off-label use): Oral: 100 mg administered 30 to 60 minutes prior to procedure; if inadvertently not given prior to the procedure, may be administered up to 2 hours after the procedure. Note: Reserve for select situations (cardiac condition with the highest risk of adverse endocarditis outcomes and procedure likely to result in bacteremia with an organism that can cause endocarditis) (Ref).

Endocarditis, treatment, oral step-down therapy in patients who inject drugs

Endocarditis, treatment, oral step-down therapy in patients who inject drugs (alternative agent) (off-label use):

Note: Not first-line treatment; data are limited. Reserve use for patients who inject drugs who had initial clinical improvement with IV treatment for methicillin-resistant S. aureus or penicillin allergy for methicillin-susceptible S. aureus infection but cannot complete IV standard of care therapy (Ref).

Oral: 100 mg twice daily for a total duration, including initial IV therapy, of 6 weeks (Ref).

Hidradenitis suppurativa

Hidradenitis suppurativa (off-label use): Oral: 100 mg once or twice daily for ≥3 months (Ref).

Lyme disease

Lyme disease (Borrelia spp. infection) (off-label use):

Prophylaxis: Oral: 200 mg as a single dose. Note: Prophylaxis is used only in patients who meet all of the following criteria: Ixodes spp. tick attached for ≥36 hours, prophylaxis can be given within 72 hours of tick removal, and local rate of Ixodes spp. tick infection with Borrelia burgdorferi is ≥20% (Ref).

Treatment, erythema migrans : Oral: 100 mg twice daily for 10 days (Ref).

Treatment, acute neurologic disease (isolated facial nerve palsy, meningitis, or radiculoneuropathy): Oral: 100 mg twice daily for 14 to 21 days (Ref).

Treatment, carditis (initial therapy for mild disease [first-degree atrioventricular block with PR interval <300 msec] or step-down therapy after initial parenteral treatment for more severe disease once PR interval <300 msec): Oral: 100 mg twice daily for 14 to 21 days (Ref).

Treatment, arthritis without neurologic involvement: Oral: 100 mg twice daily for 28 days (Ref).

Malaria

Malaria:

Prophylaxis: Oral (immediate release and delayed release): 100 mg daily; initiate 1 to 2 days prior to travel to endemic area; continue daily during travel and for 4 weeks after leaving endemic area.

Treatment (alternative agent) (off-label use): Oral: 100 mg twice daily for 7 days, as part of an appropriate combination regimen. Note: If used for P. vivax or P. ovale, use this regimen in combination with primaquine. If used for severe malaria (after completion of IV therapy), use full 7-day schedule of doxycycline (Ref).

Otitis media, acute

Otitis media, acute (alternative agent if unable to tolerate penicillins and cephalosporins) (off-label use): Oral: 100 mg every 12 hours; duration of therapy is 5 to 7 days (mild to moderate infection) or 10 days (severe infection) (Ref).

Periodontitis, severe, plaque-associated

Periodontitis, severe, plaque-associated:

Note: For anti-collagenolytic activity following acute treatment (Ref).

Subantimicrobial dosing: Oral: Immediate release: 20 mg twice daily for 3 to 9 months; use in addition to periodontal debridement (Ref).

Plague

Plague (Yersinia pestis):

Note: Consult public health officials for event-specific recommendations.

Postexposure prophylaxis: Oral: 100 mg every 12 hours for 7 days (Ref).

Treatment of bubonic, pharyngeal, pneumonic, or septicemic plague (alternative agent for pneumonic or septicemic plague): Oral, IV: 200 mg initially, then 100 mg every 12 hours for 10 to 14 days and for at least a few days after clinical resolution (Ref).

Patients who are pregnant (alternative agent): Oral, IV: 200 mg IV initially, then 100 mg orally or IV every 12 hours or 200 mg IV every 24 hours (Ref).

Pleurodesis, chemical

Pleurodesis, chemical (sclerosing agent for pleural effusion) (off-label use): Intrapleural: 500 mg as a single dose in 30 to 100 mL NS (Ref). Some experts combine with or administer following instillation of a local anesthetic (eg, lidocaine, 10 to 25 mL [100 to 250 mg] of 1% solution (Ref) or mepivacaine 20 mL [400 mg] of 2% solution (Ref)).

Pneumonia, community-acquired, empiric therapy

Pneumonia, community-acquired, empiric therapy:

Outpatients with no risk factors for antibiotic resistant pathogens: Oral: 100 mg twice daily; must be used as part of an appropriate combination regimen in outpatients with comorbidities (Ref). Some experts prefer to use as part of an appropriate combination regimen in all outpatients, regardless of comorbidities (Ref).

Inpatients (alternative agent): Oral, IV: 100 mg twice daily as part of an appropriate combination regimen (Ref).

Duration: Minimum of 5 days; patients should be clinically stable with normal vital signs before discontinuing therapy (Ref).

Prosthetic joint infection

Prosthetic joint infection (off-label use):

Treatment: Oral continuation therapy for S. aureus (following pathogen-specific IV therapy in patients undergoing 1-stage exchange or debridement with retention of prosthesis) (alternative agent): Oral: 100 mg twice daily in combination with rifampin; total duration is a minimum of 3 months, depending on patient-specific factors (Ref).

Chronic suppression for staphylococci (methicillin resistant) and Cutibacterium acnes (alternative agent for C. acnes): Oral: 100 mg twice daily (Ref).

Q fever

Q fever (C. burnetii) :

Acute symptomatic infection: Note: Treatment is most effective if given within the first 3 days of symptoms (Ref).

Oral: 100 mg every 12 hours for 14 days (Ref). Note: Some experts use in combination with hydroxychloroquine for 12 months in select patients (eg, those with acute Q fever and preexisting valvulopathy) (Ref).

Chronic infection (eg, endocarditis, osteoarticular infection, vascular infection): Oral: 100 mg every 12 hours in combination with hydroxychloroquine. Duration is 18 to 24 months for endocarditis or vascular infection and 12 months in patients who are postpartum with serologic profile consistent with chronic Q fever (Ref).

Rhinosinusitis, acute bacterial

Rhinosinusitis, acute bacterial (alternative agent):

Note: In uncomplicated acute bacterial rhinosinusitis, initial observation and symptom management without antibiotic therapy is appropriate in most patients. Reserve antibiotic therapy for poor follow-up or lack of improvement over the observation period (Ref).

Oral: 200 mg/day in 1 to 2 divided doses for 5 to 7 days (Ref).

Rocky Mountain spotted fever

Rocky Mountain spotted fever: Oral, IV: 100 mg twice daily for 5 to 7 days or for at least 3 days after fever subsides, whichever is longer; initiate treatment as soon as possible. Severe or complicated disease may require longer treatment (Ref). Note: Some experts recommend an initial loading dose of 200 mg for critically ill patients (Ref).

Rosacea

Rosacea:

Moderate to severe or unresponsive to topical therapy:

Traditional dosing (off label): Oral: Initial: 50 to 100 mg twice daily for 4 to 12 weeks; may follow with a topical agent and/or subantimicrobial doxycycline dosing for long-term management. Alternatively, may initiate therapy with subantimicrobial dosing (Ref).

Subantimicrobial dosing: Oral: 40 mg once daily (delayed release; Oracea) or 20 mg twice daily (immediate release) (Ref).

Papulopustular lesions, breakthrough flares: Oral: 100 mg twice daily for 10 days; continue topical maintenance therapy during and after oral treatment (Ref).

Sexually transmitted infections

Sexually transmitted infections:

Cervical infection, empiric therapy for cervicitis or pathogen-directed therapy for Chlamydia trachomatis: Oral: 100 mg twice daily for 7 days (Ref) or 200 mg delayed release once daily for 7 days (Ref); for empiric therapy, give in combination with ceftriaxone if the patient is at high risk for gonorrhea, if follow up is a concern, or if local prevalence of gonorrhea is elevated (>5%) (Ref).

Empiric treatment following sexual assault (off-label use): Oral: 100 mg twice daily for 7 days, as part of an appropriate combination regimen (Ref).

Epididymitis, acute (off-label use): Empiric therapy for chlamydia and gonorrhea: Oral: 100 mg twice daily for 10 days with single dose of ceftriaxone. Note: An alternative regimen is recommended in patients who practice insertive anal sex (Ref).

Granuloma inguinale (donovanosis) (alternative agent): Oral: 100 mg twice daily for >3 weeks and until resolution of lesions. Note: If symptoms do not improve within the first few days of therapy, addition of a second agent may be considered (Ref).

Lymphogranuloma venereum: Oral: 100 mg twice daily for 21 days (Ref).

Pelvic inflammatory disease (off-label use):

Mild to moderate pelvic inflammatory disease, outpatient therapy: Oral: 100 mg every 12 hours for 14 days as part of an appropriate combination regimen (Ref).

Severe pelvic inflammatory disease, inpatient therapy: Oral, IV: 100 mg every 12 hours as part of an appropriate combination regimen; transition to oral therapy after 24 to 48 hours of sustained clinical improvement to complete a 14-day total course (Ref).

Postexposure prophylaxis, bacterial infections (off-label use):

Note: Reserve use for selected men or transgender women who have sex with men and are at high risk for bacterial sexually transmitted infections. Long-term effects on bacterial resistance are unknown (Ref).

Oral (immediate release and delayed release): 200 mg as a single dose; administer within 24 hours but no later than 72 hours after condomless sex (Ref). Maximum dose: 200 mg once every 24 hours (Ref).

Rectal infection, empiric therapy for acute proctitis or proctocolitis or pathogen-directed therapy for Chlamydia trachomatis (off-label use): Oral: 100 mg twice daily for 7 days; for empiric therapy, give in combination with a single dose of ceftriaxone. Note: Extend doxycycline duration to 21 days for presumptive therapy of lymphogranuloma venereum if patient has severe rectal symptoms (eg, bloody discharge, tenesmus, perianal ulcers or mucosal ulcers) and a positive rectal chlamydia NAAT or HIV infection (Ref).

Syphilis (alternative agent for nonpregnant patients with penicillin allergy):

Note: Limited data support use of doxycycline as an alternative to penicillin, and close serologic and clinical follow-up is warranted (Ref).

Early syphilis (primary, secondary, and early latent [<1-year duration]): Oral: 100 mg twice daily for 14 days (Ref).

Late syphilis (late latent [>1-year duration] or tertiary syphilis with normal CSF examination): Note: For tertiary syphilis, reserve use for patients who are unable to be desensitized to penicillin (Ref).

Oral: 100 mg twice daily for 28 days (Ref).

Urethral infection, empiric therapy for urethritis or pathogen-directed therapy for Chlamydia trachomatis: Oral: 100 mg twice daily for 7 days or 200 mg delayed release once daily for 7 days (Ref); give in combination with ceftriaxone if there is microscopic evidence of gonococcal urethritis or if there is high clinical suspicion of gonococcal infection (Ref).

Skin and soft tissue infection

Skin and soft tissue infection:

Abscess:

Note: Systemic antibiotics may be reasonably withheld in healthy, immunocompetent patients with a single, small abscess that has been drained if they are clinically well and have no indwelling device, risk factors for endocarditis, or risk for methicillin-resistant S. aureus transmission (Ref).

Oral: 100 mg twice daily for ≥5 days but may extend up to 14 days depending on severity and clinical response (Ref).

Cellulitis, purulent or with risk for methicillin-resistant S. aureus: Oral: 100 mg twice daily in combination with an additional agent (eg, amoxicillin, cephalexin) for coverage of beta-hemolytic streptococci. Treat for ≥5 days but may extend up to 14 days depending on severity and clinical response (Ref).

Impetigo or ecthyma if methicillin-resistant S. aureus is suspected or confirmed: Note: For impetigo, reserve systemic therapy for patients with numerous lesions or in outbreak settings to decrease transmission (Ref).

Oral: 100 mg twice daily for 7 days (Ref).

Surgical prophylaxis, uterine evacuation

Surgical prophylaxis, uterine evacuation (induced abortion or pregnancy loss) (off-label use): Oral: 200 mg as a single dose 1 hour prior to uterine aspiration (Ref); may be administered up to 12 hours before the procedure (Ref). Note: The optimal dosing regimen has not been established; various protocols are in use (Ref).

Tularemia

Tularemia (Francisella tularensis):

Treatment (mild infection) (alternative agent): Oral: 100 mg twice daily for 14 to 21 days (Ref).

Postexposure prophylaxis (nonbioterrorism event, high-risk exposure): Oral: 100 mg twice daily for 14 days (Ref).

Bioterrorism event: Note: Consult public health officials for event-specific recommendations.

Mass casualty management or postexposure prophylaxis (when used as a biological weapon): Oral: 100 mg twice daily for 14 days (Ref).

Contained casualty management (when used as a biological weapon): IV (may transition to oral if clinically appropriate): 100 mg every 12 hours for 14 to 21 days (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

IV, Oral:

Mild to severe impairment: No dosage adjustment necessary (Ref)

Hemodialysis, intermittent (thrice weekly): Poorly dialyzed (0% to 5%); no supplemental dose or dosage adjustment necessary (Ref).

Peritoneal dialysis: Poorly dialyzed; no dosage adjustment necessary (Ref).

CRRT: No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (Ref).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Doxycycline: Pediatric drug information")

Dosage guidance:

Dosing: Doxycycline is available as hyclate, monohydrate, and calcium salts. Modified polymer-coated tablet (Doryx MPC) is not substitutable with other doxycycline products on a milligram-to-milligram basis; modified polymer-coated tablet (Doryx MPC) 120 mg is equivalent to conventional delayed-release tablet 100 mg. All doses are expressed as doxycycline non–polymer-coated base; dosage conversion necessary if using polymer-coated product (Doryx MPC). See specific manufacturer labeling for product details.

Clinical considerations: Doxycycline was traditionally avoided in ages <8 years, but use has more recently been accepted for short courses (<21 days) for all ages when necessary (Ref).

General dosing: Children and Adolescents: Oral, IV: 2.2 mg/kg/dose every 12 hours; maximum dose: 100 mg/dose (Ref).

Acne vulgaris, moderate to severe, treatment

Acne vulgaris, moderate to severe, treatment: Limited data available: Children ≥8 years and Adolescents: Oral: 50 to 100 mg once or twice daily or 150 mg once daily (Ref).

Anthrax

Anthrax (Ref): Note: Consult public health officials for event-specific recommendations.

Prophylaxis; postexposure (inhalation or cutaneous); prior to susceptibility testing or penicillin-resistant strains: Note: Doxycycline is a preferred option or ciprofloxacin: Infants, Children, and Adolescents: Treatment duration: 60 days.

Patient weight <45 kg: Oral: 2.2 mg/kg/dose every 12 hours.

Patient weight ≥45 kg: Oral: 100 mg every 12 hours.

Treatment; susceptible strains:

Cutaneous infection without systemic involvement: Note: Doxycycline is an option if first-line therapy (ie, ciprofloxacin) is unavailable or patient unable to tolerate; for naturally-occurring infection, usual treatment duration is 7 to 10 days; in the event of biological weapon exposure, additional therapy (as prophylaxis for inhaled spores) is necessary for a total course of 60 days from onset of illness.

Infants, Children, and Adolescents:

Patient weight <45 kg: Oral: 2.2 mg/kg/dose every 12 hours.

Patient weight ≥45 kg: Oral: 100 mg every 12 hours.

Systemic anthrax, excluding meningitis: Note: Not recommended for meningitis or disseminated infection when meningitis cannot be ruled out. Doxycycline is an alternative to clindamycin as protein synthesis inhibitor and should be used in combination with a bactericidal antimicrobial (eg, fluoroquinolone, carbapenem, vancomycin). Duration of therapy at least 14 days or longer until patient clinically stable; additional therapy (as prophylaxis for inhaled spores) is necessary for a total course of 60 days from onset of illness.

Infants, Children, and Adolescents:

Patient weight <45 kg:

Initial: IV: Loading dose: 4.4 mg/kg once, then 2.2 mg/kg/dose every 12 hours; may transition to oral therapy for patients without signs of active infection who are able to tolerate oral therapy and patient/caregiver adherent to therapy.

Step-down: Oral: 2.2 mg/kg/dose every 12 hours.

Patient weight ≥45 kg:

Initial: IV: Loading dose: 200 mg once, then 100 mg every 12 hours; may transition to oral therapy for patients without signs of active infection who are able to tolerate oral therapy and patient/caregiver adherent to therapy.

Step-down: Oral: 100 mg every 12 hours.

Brucellosis

Brucellosis: Limited data available: Children ≥8 years and Adolescents: Oral: 2.2 mg/kg/dose twice daily for at least 6 weeks; maximum dose: 100 mg/dose; use in combination with rifampin; for serious infections, gentamicin should be added for initial 1 to 2 weeks and therapy may be extended for up to 4 to 6 months (Ref).

Chlamydial infections, uncomplicated

Chlamydial infections, uncomplicated (sexually transmitted C. trachomatis):

Children ≥8 years: Oral: 2.2 mg/kg/dose twice daily for 7 days. Maximum dose: 100 mg/dose (Ref).

Adolescents: Oral: 100 mg twice daily for 7 days (Ref).

Cholera, treatment

Cholera (Vibrio cholerae), treatment: Note: Due to resistance concerns, antibiotic choice during an outbreak or epidemic should be guided by local isolate susceptibility (Ref).

Children <6 years: Oral: 4 mg/kg as a single dose in combination with hydration; maximum dose: 300 mg/dose (Ref). Note: In children ≥6 years of age, a higher dose of 6 mg/kg was associated with a slightly shorter duration of diarrhea; data with 6 mg/kg are not available for children <6 years of age (Ref). Although doses as low as 2 mg/kg have been recommended, they represent a lower dosing strategy as compared to 300 mg adult dose (Ref).

Children ≥6 years and Adolescents: Oral: 4 to 6 mg/kg as a single dose in combination with hydration; maximum dose: 300 mg/dose (Ref). Note: Although doses as low as 2 mg/kg have been recommended, they represent a lower dosing strategy as compared to 300 mg adult dose (Ref).

Endocarditis, prophylaxis before invasive dental procedures

Endocarditis, prophylaxis before invasive dental procedures (alternative agent): Limited data available:

Note: Alternative agent for use in patients with penicillin or ampicillin allergy. Recommended only in patients who are at highest risk for infective endocarditis (IE) or adverse outcomes (eg, history of IE, cardiac valve repair using prosthetic valves or material, unrepaired cyanotic congenital heart disease [CHD], left ventricular assist device or implantable heart, repaired CHD with prosthetic material or device during first 6 months after procedure, pulmonary artery valve or conduit placement [eg, Melody valve, Contegra conduit], repaired CHD with residual defects at the site or adjacent to site of prosthetic patch or device, heart transplant recipients with cardiac valvulopathy) (Ref).

Infants, Children, and Adolescents: Oral: 2.2 mg/kg as a single dose administered 30 to 60 minutes prior to dental procedure; maximum dose: 100 mg/dose (Ref).

Lyme disease

Lyme disease (Borrelia spp. infection): Limited data available:

Prophylaxis, postexposure: Infants, Children, and Adolescents: Oral: 4.4 mg/kg/dose as a single dose; maximum dose: 200 mg/dose. Note: Prophylaxis is used only in patients who meet all of the following criteria for a high-risk bite: Ixodes spp. tick attached for ≥36 hours, prophylaxis can be given within 72 hours of tick removal, and tick bite occurred in a highly endemic area (ie, local rate of Ixodes spp. tick infection with Borrelia burgdorferi is ≥20%) (Ref).

Treatment: Infants, Children, and Adolescents: Oral: 2.2 mg/kg/dose twice daily; maximum dose: 100 mg/dose. Duration of therapy depends on clinical syndrome; treat erythema migrans for 10 days; borrelial lymphocytoma for 14 days; meningitis, radiculopathy, cranial nerve palsy, or carditis for 14 to 21 days; arthritis (initial, recurrent, or refractory) for 28 days; and acrodermatitis chronica atrophicans for 21 to 28 days (Ref).

Malaria

Malaria:

Prophylaxis: Children ≥8 years and Adolescents: Oral: 2.2 mg/kg/dose once daily starting 1 to 2 days before travel to the area with endemic infection, continuing daily during travel and for 4 weeks after leaving endemic area; maximum daily dose: 100 mg/day (Ref).

Treatment: Children and Adolescents: Oral, IV: 2.2 mg/kg/dose twice daily for 7 days; maximum dose: 100 mg/dose; use in combination with quinine sulfate (plus primaquine for Plasmodium vivax) (Ref). Note: Use of doxycycline in children <8 years should be reserved for when alternatives are not available or are not tolerated; benefits should outweigh risks (Ref).

Pneumonia, community-acquired; presumed or proven atypical infection

Pneumonia, community-acquired; presumed or proven atypical infection (Mycoplasma pneumoniae, Chlamydophila pneumoniae): Children ≥8 years and Adolescents: Oral: 1 to 2 mg/kg/dose twice daily for 10 days (Ref).

Q fever

Q fever ( Coxiella burnetii): Children and Adolescents: Oral: 2.2 mg/kg/dose twice daily for 14 days; maximum dose: 100 mg/dose. In children <8 years with mild or uncomplicated disease, may consider treatment duration of 5 days (Ref). For treatment of endocarditis or chronic disease in patients ≥8 years of age, use in combination with hydroxychloroquine for 18 to 36 months (Ref).

Skin/soft tissue infections; MRSA or community-acquired cellulitis

Skin/soft tissue infections; MRSA or community-acquired cellulitis (purulent) (Ref):

Children ≥8 years and Adolescents:

≤45 kg: Oral: 2 mg/kg/dose every 12 hours for 5 to 10 days.

>45 kg: Oral: 100 mg twice daily for 5 to 10 days.

Tickborne rickettsial disease, ehrlichiosis, or anaplasmosis

Tickborne rickettsial disease (Rocky Mountain spotted fever), ehrlichiosis, or anaplasmosis: Children and Adolescents: Oral, IV: 2.2 mg/kg/dose every 12 hours; maximum dose: 100 mg/dose; treat for minimum of 5 to 7 days; continue for at least 3 days after defervescence and clinical improvement observed. Severe or complicated disease may require longer treatment; anaplasmosis should be treated for 10 days (Ref).

Tularemia

Tularemia ( Francisella tularensis ):

Postexposure prophylaxis: Children and Adolescents: Oral: 2.2 mg/kg/dose every 12 hours for 14 days; maximum dose: 100 mg/dose (Ref).

Treatment (alternative agent): Children and Adolescents: Oral, IV: 2.2 mg/kg/dose every 12 hours for 14 to 21 days; maximum dose: 100 mg/dose. For bioterrorism events: Contained casualty: 14 to 21 days of therapy, with therapy initiated IV; Mass casualty: 14 days of oral treatment is recommended (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Children and Adolescents: IV, Oral: Limited data available:

Altered kidney function: Mild to severe kidney impairment: Based on adult information, no dosage adjustment is necessary (Ref).

Hemodialysis, intermittent: Poorly dialyzed (0% to 5%); based on adult information, no supplemental dose or dosage adjustment necessary (Ref).

Peritoneal dialysis: Poorly dialyzed; based on adult information, no dosage adjustment necessary (Ref).

Continuous renal replacement therapy (CRRT): Based on adult information, no dosage adjustment necessary (Ref).

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions (Significant): Considerations
Bone growth suppression

Bone growth suppression, as evidenced by growth retardation (fibula), has been reported in premature infants treated with tetracycline; growth restriction up to 40% has been associated with oral tetracycline therapy but is reversible when short-term treatment is discontinued. Upon discontinuation of tetracycline, rapid compensatory bone growth is observed (Ref). There are limited/no data with doxycycline; therefore, the risk for bone growth suppression is extrapolated from data with tetracycline.

Mechanism: Dose-related; tetracycline binds to calcium in growing bones and negatively affects calcium orthophosphate metabolism (Ref); doxycycline appears to bind to calcium less than tetracycline (Ref).

Onset: Intermediate; deposition of tetracycline in bone has been shown after one dose and treatment with tetracycline for 9 to 12 days has resulted in restricted bone growth (Ref).

Risk factors:

• Dose; tetracycline 25 mg/kg/dose every 6 hours in premature infants (Ref)

• Age: Premature infants (Ref)

Esophageal injury

Esophagitis, esophageal ulcer, and/or esophageal stenosis may occur; patients with sudden onset of chest pain, dysphagia, odynophagia, and/or retrosternal pain may require assessment (Ref). Esophagitis is more frequent with doxycycline than minocycline (Ref).

Mechanism: Local caustic injury due to direct local contact as doxycycline has a pH <3 (Ref).

Onset: Varied; 3 to 12 days after initiation. In treatment of chronic conditions such as acne vulgaris, it can occur any time during treatment (Ref).

Risk factors:

• Administration at bedtime or prior to lying down (Ref)

• Altered esophageal anatomy or underlying esophageal strictures

• Inadequate fluid intake with administration (Ref)

• Preexisting esophageal disorders (eg, gastroesophageal reflux disease)

Photosensitivity

Doxycycline may cause skin photosensitivity reactions ranging from mild sunburn-like reactions to photodermatitis (Ref). Phototoxic reactions are restricted to exposed skin, usually develop shortly after sun exposure and appear to be dose-related (Ref). Photo-onycholysis has also been reported with tetracyclines (Ref). The main wavelength causing doxycycline’s phototoxic reactions is UVA1 (340-400 nm) (Ref). Chronic tetracycline use (>2 months) may increase the risk of basal cell carcinoma by 11% (Ref).

Mechanism: Doxycycline is activated by the radiation in the long UVA1 spectrum (340-400 nm), increasing sensitivity to sunlight (Ref).

Onset: Photosensitivity: Occurs <24 hours after sun exposure (Ref).

Risk factors:

• Children even at very low doses (20 mg daily) may have increased susceptibility (Ref)

• Fitzpatrick skin types I and II (white, always burns, never tans or tans minimally) (Ref)

• Higher doses (Ref)

• Lack of adherence to suggested sun avoidance, sun-protective clothing, and broad- spectrum sunscreen (UVA and UVB) (Ref)

• Living in a country with high solar radiation; even low doses can precipitate a reaction (Ref)

• Use of sunscreens with primary UVA protection offered by oxybenzone (absorbs shorter UVA radiation) (Ref)

Skin hyperpigmentation/dental discoloration

Doxycycline may induce diffuse skin hyperpigmentation (brown, bluish-grey, black discoloration) including nails, skin of hands, arms, legs, dorsal side of feet, interdigital areas, or around scars. Risk of dental staining (staining of tooth) and enamel hypoplasia with doxycycline during tooth development is controversial; however, studies have not validated these issues and most recommend short-term use (<21 days) in children regardless of age (Ref). Local pain with the change in pigment has been reported (Ref). Many patients were receiving doxycycline at higher doses for prolonged periods of time as in treatment of Q fever. For treatment of Q fever, doxycycline is administered concurrently with hydroxychloroquine, which also may cause skin hyperpigmentation (Ref). Hyperpigmentation may be more prevalent with minocycline than doxycycline and associated with a greater variety of tissues (eg, bone, conjunctiva and sclera, ear tympanic membrane, internal organs, nails, subcutaneous fat, teeth and oral mucosa, and thyroid) (Ref). Partially reversible or reversible within 1 to 12 months of discontinuation (Ref).

Mechanism: Dose- and time-related; doxycycline may mineralize tissue as it binds to calcium/iron to form a tetracycline-calcium/iron orthophosphate complex and/or activate melanocytes in the upper dermis (Ref).

Onset: Varied; 2 weeks to 37 months (Ref).

Risk factors:

• Higher doses (Ref)

• Long-term use (Ref)

• Pediatric: Treatment course >21 days (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

1% to 10%:

Endocrine & metabolic: Increased lactate dehydrogenase (2%), increased serum glucose (1%)

Gastrointestinal: Abdominal distention (1%), abdominal pain (1%), diarrhea (5%), upper abdominal pain (2%), xerostomia (1%)

Genitourinary: Vulvovaginal candidiasis

Postmarketing:

Dermatologic: Basal cell carcinoma of skin (chronic use) (Li 2018), erythema multiforme (Shapiro 1997), erythematous rash, exfoliative dermatitis, maculopapular rash, onycholysis (photo-onycholysis skin hyperpigmentation; chronic use) (Dowlati 2015), skin hyperpigmentation (Akcam 2005; Keijmel 2015), skin photosensitivity (Goetze 2017; Lebrun 2012; Shapiro 1997), Stevens-Johnson syndrome (Cac 2007; Shapiro 1997), urticaria (Shapiro 1997)

Endocrine & metabolic: Growth retardation (fibula; based on tetracycline data) (Cohlan 1963)

Gastrointestinal: Anorexia, Clostridioides difficile-associated diarrhea (not associated with increased risk) (Deshpanda 2013; Tariq 2018), enamel hypoplasia (Stultz 2019), enterocolitis, esophageal stenosis (Bonavina 1989), esophageal ulcer (Guo 2019), esophagitis (Kim 2014), glossitis, nausea (Shapiro 1997), staining of tooth (Stultz 2019), vomiting (Shapiro 1997)

Hepatic: Hepatotoxicity (including hepatic coma, hepatic failure, hepatic necrosis, toxic hepatitis) (Björnsson 1997; Heaton 2007)

Hypersensitivity: Angioedema (Shapiro 1997), drug reaction with eosinophilia and systemic symptoms (Lebrun-Vignes 2012), hypersensitivity reaction (Shapiro 1997), nonimmune anaphylaxis (Raeder 1984), serum sickness (Shapiro 1997)

Nervous system: Bulging fontanel (based on tetracycline data) (Fields 1961; Opfer 1963), intracranial hypertension (causality not established; females of childbearing age who are overweight or have a history of intracranial hypertension may be at greater risk)

Neuromuscular & skeletal: Exacerbation of systemic lupus erythematosus

Renal: Increased blood urea nitrogen

Contraindications

Hypersensitivity to doxycycline, other tetracyclines, or any component of the formulation.

Doxytab, JAMP-doxycycline [Canadian products]: Additional contraindications: Myasthenia gravis; concurrent use with isotretinoin.

Periostat, Apprilon [Canadian products]: Additional contraindications: Use in infants and children <8 years of age or during second or third trimester of pregnancy; breast-feeding.

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Warnings/Precautions

Concerns related to adverse effects:

• Increased BUN: May be associated with increases in BUN secondary to antianabolic effects; this does not occur with use of doxycycline in patients with renal impairment.

• Intracranial hypertension: Intracranial hypertension (pseudotumor cerebri) has been reported; headache, blurred vision, diplopia, vision loss, and/or papilledema may occur. Women of childbearing age who are overweight or have a history of intracranial hypertension are at greater risk. Intracranial hypertension typically resolves after discontinuation of treatment; however, permanent visual loss is possible. If visual symptoms develop during treatment, prompt ophthalmologic evaluation is warranted. Intracranial pressure can remain elevated for weeks after drug discontinuation; monitor patient until stable.

• Superinfection: Prolonged use may result in fungal or bacterial superinfection.

Disease-related concerns

• Oral candidiasis: Safety and effectiveness have not been established for treatment of periodontitis in patients with coexistent oral candidiasis; use with caution in patients with a history or predisposition to oral candidiasis.

Special populations:

• Neonatal: Preterm neonates receiving oral tetracycline experienced a reversible decrease in fibular growth rate; data with doxycycline are unavailable; use caution (Cohlan 1963; manufacturer's labeling).

• Pediatric: Due to risks of permanent tooth staining, manufacturers generally recommend to use tetracycline antibiotics in patients <8 years of age only when benefits outweigh the risks; however, studies have not validated the concern for tooth staining with short-term use of doxycycline (<21 days) and short-term use is considered acceptable in children regardless of age (CDC [Biggs 2016]; Lochary 1998; Pöyhönen 2017; Red Book [AAP 2021]; Stultz 2019; Todd 2015; Wormser 2019).

Dosage form specific issues:

• Oracea, Apprilon [Canadian product]: Should not be used for the treatment or prophylaxis of bacterial infections because the lower dose of drug per capsule may be subefficacious and promote resistance.

• Sulfite sensitivity: Syrup may contain sodium metabisulfite, which may cause allergic reactions in certain individuals (eg, asthmatic patients).

Other warnings/precautions:

• Appropriate use: Acne: The American Academy of Dermatology acne guidelines recommend doxycycline as adjunctive treatment for moderate and severe acne and forms of inflammatory acne that are resistant to topical treatments. Concomitant topical therapy with benzoyl peroxide or a retinoid should be administered with systemic antibiotic therapy (eg, doxycycline) and continued for maintenance after the antibiotic course is completed (AAD [Zaenglein 2016]).

• Limitations of use: Malaria prophylaxis: Doxycycline does not completely suppress asexual blood stages of Plasmodium strains; does not suppress P. falciparum's sexual blood stage gametocytes. Patients completing a regimen may still transmit the infection to mosquitoes outside endemic areas.

Warnings: Additional Pediatric Considerations

Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).

Dosage Forms Considerations

Morgidox kits contain doxycycline capsules 100 mg, plus AcuWash moisturizing Daily Cleanser

NizAzel Doxy kits contain doxycycline tablets 100 mg, plus NicAzel FORTE dietary supplement tablets

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral, as hyclate [strength expressed as base]:

Morgidox: 100 mg [DSC] [contains fd&c blue #1 (brilliant blue)]

Vibramycin: 100 mg [contains fd&c blue #1 (brilliant blue)]

Generic: 50 mg, 100 mg

Capsule, Oral, as monohydrate [strength expressed as base]:

Mondoxyne NL: 75 mg [DSC], 100 mg [contains quinoline yellow (d&c yellow #10)]

Okebo: 75 mg [DSC]

Generic: 50 mg, 75 mg, 100 mg, 150 mg

Capsule Delayed Release, Oral, as monohydrate [strength expressed as base]:

Oracea: 40 mg

Generic: 40 mg

Kit, Combination, as hyclate [strength expressed as base]:

Morgidox: 1 x 100 mg [DSC], 2 x 100 mg [DSC] [contains cetyl alcohol, edetate (edta) disodium, fd&c blue #1 (brilliant blue)]

Solution Reconstituted, Intravenous, as hyclate [strength expressed as base]:

Generic: 100 mg (1 ea)

Solution Reconstituted, Intravenous, as hyclate [strength expressed as base, preservative free]:

Doxy 100: 100 mg (1 ea)

Generic: 100 mg (1 ea)

Suspension Reconstituted, Oral, as monohydrate [strength expressed as base]:

Vibramycin: 25 mg/5 mL (60 mL) [contains fd&c blue #1 (brilliant blue), methylparaben, propylparaben; raspberry flavor]

Generic: 25 mg/5 mL (60 mL)

Syrup, Oral, as calcium [strength expressed as base]:

Vibramycin: 50 mg/5 mL (473 mL [DSC]) [contains butylparaben, propylene glycol, propylparaben, sodium metabisulfite]

Tablet, Oral, as hyclate [strength expressed as base]:

Acticlate: 75 mg [DSC] [contains fd&c blue #1 (brilliant blue), fd&c yellow #6 (sunset yellow)]

Acticlate: 150 mg [DSC] [scored; contains fd&c blue #2 (indigotine,indigo carmine)]

Lymepak: 100 mg [DSC] [contains fd&c blue #1 (brilliant blue), fd&c yellow #6 (sunset yellow), quinoline yellow (d&c yellow #10)]

TargaDOX: 50 mg [contains fd&c blue #2 (indigotine,indigo carmine), fd&c yellow #6 (sunset yellow)]

Generic: 20 mg, 50 mg, 75 mg, 100 mg, 150 mg

Tablet, Oral, as monohydrate [strength expressed as base]:

Avidoxy: 100 mg [contains fd&c yellow #6(sunset yellow)alumin lake, quinoline (d&c yellow #10) aluminum lake]

Generic: 50 mg, 75 mg, 100 mg, 150 mg

Tablet Delayed Release, Oral, as hyclate:

Doryx MPC: 60 mg [contains corn starch]

Tablet Delayed Release, Oral, as hyclate [strength expressed as base]:

Doryx: 50 mg [contains corn starch]

Doryx: 80 mg [DSC], 200 mg [DSC] [scored; contains corn starch]

Doryx MPC: 120 mg [contains corn starch]

Generic: 50 mg, 75 mg, 80 mg, 100 mg, 150 mg, 200 mg

Generic Equivalent Available: US

May be product dependent

Pricing: US

Capsule, delayed release (Oracea Oral)

40 mg (per each): $36.56

Capsules (Doxycycline Hyclate Oral)

50 mg (per each): $2.16 - $2.25

100 mg (per each): $0.38 - $9.62

Capsules (Doxycycline Monohydrate Oral)

50 mg (per each): $1.45 - $1.55

75 mg (per each): $16.40 - $16.92

100 mg (per each): $2.13 - $2.56

150 mg (per each): $24.65

Capsules (Mondoxyne NL Oral)

100 mg (per each): $10.52

Capsules (Vibramycin Oral)

100 mg (per each): $1.09

Solution (reconstituted) (Doxy 100 Intravenous)

100 mg (per each): $25.20

Solution (reconstituted) (Doxycycline Hyclate Intravenous)

100 mg (per each): $17.61 - $30.20

Suspension (reconstituted) (Doxycycline Monohydrate Oral)

25 mg/5 mL (per mL): $0.38

Suspension (reconstituted) (Vibramycin Oral)

25 mg/5 mL (per mL): $0.83

Tablet, EC (Doryx MPC Oral)

60 mg (per each): $24.00

120 mg (per each): $15.00

Tablet, EC (Doryx Oral)

50 mg (per each): $14.22

Tablet, EC (Doxycycline Hyclate Oral)

50 mg (per each): $11.73 - $13.51

75 mg (per each): $10.22

80 mg (per each): $39.58

100 mg (per each): $13.15

150 mg (per each): $17.60

200 mg (per each): $43.42 - $50.01

Tablets (Doxycycline Hyclate Oral)

20 mg (per each): $0.74 - $1.30

50 mg (per each): $13.20

75 mg (per each): $31.15 - $31.19

100 mg (per each): $2.62 - $6.15

150 mg (per each): $31.15 - $31.19

Tablets (Doxycycline Monohydrate Oral)

50 mg (per each): $2.89 - $3.36

75 mg (per each): $4.93 - $4.99

100 mg (per each): $4.23 - $4.92

150 mg (per each): $9.14

Tablets (TargaDOX Oral)

50 mg (per each): $17.86

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Periostat: 20 mg

Capsule, Oral, as hyclate [strength expressed as base]:

Generic: 100 mg

Capsule Delayed Release, Oral, as monohydrate [strength expressed as base]:

Apprilon: 40 mg

Generic: 40 mg

Tablet, Oral, as hyclate [strength expressed as base]:

Generic: 100 mg

Administration: Adult

Oral administration is preferable unless patient has significant nausea and vomiting; IV and oral routes are bioequivalent.

Oral: In general, administer with meals to decrease GI upset; however, some manufacturer labeling recommends administration on an empty stomach (see below). Administer capsules and tablets with at least 8 ounces (240 mL) of water and have patient sit up for at least 30 minutes or 1 to 2 hours (Canadian labeling) after taking to reduce the risk of esophageal irritation and ulceration.

Acticlate: Swallow capsule whole; do not break, open, crush, dissolve, or chew. The 150 mg tablet may be broken into 2/3 or 1/3 to provide a 100 mg and 50 mg strength, respectively.

Doxycycline 20 mg tablet, Oracea, Apprilon [Canadian product]: Administer on an empty stomach 1 hour before or 2 hours after meals.

Doryx: Do not chew or crush tablets. May be administered by carefully breaking up the tablet and sprinkling tablet contents on a spoonful of cold applesauce; applesauce should be soft enough to swallow without chewing. The delayed-release pellets must not be crushed or damaged when breaking up tablet. Should be administered immediately after preparation and without chewing; follow with a cool 8-ounce (240 mL) glass of water to ensure complete swallowing. If applesauce/pellet mixture is not administered immediately, discard (do not store for future use).

Doryx MPC: Do not chew or crush tablets.

JAMP-doxycycline [Canadian product]: Administer with a full glass of water and with or after a meal to minimize GI upset; patient should not lay down after administration and should not go to bed within 1 to 2 hours of administration.

Periostat [Canadian product]: Administer 1 hour before breakfast and evening meal.

Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate.

Capsule, delayed release: Delayed-release capsule may not be opened. Switch to IR formulation (capsule, tablet, or oral suspension) at closest possible dose.

Tablet, extended release: Delayed-release tablet can be cut into small pieces but not crushed.

IV : For IV use only. Infuse slowly, usually over 1 to 4 hours. Avoid extravasation (may be an irritant). Duration of IV therapy should be minimized, when possible, to avoid risk of thrombophlebitis. IV and oral routes are bioequivalent.

Intrapleural (off-label route): Instill diluted doxycycline (combined with or following instillation of a local anesthetic) into chest tube; clamp chest tube for 2 hours (Ref).

Administration: Pediatric

Oral: Administer capsules or tablets with adequate amounts of fluid and remain in an upright position following administration (to avoid esophageal irritation); may be administered with food or milk to decrease GI upset (though absorption may be slightly reduced). Shake suspension well before use.

Acticlate:

Capsule: Swallow capsule whole; do not break, open, crush, dissolve, or chew the capsule.

Tablet (150 mg): May be broken into 1/3 to provide 50 mg dose or 2/3 to provide 100 mg/dose.

Doryx: May break up the tablet and sprinkle the delayed-release pellets on a spoonful of applesauce. Do not crush or damage the delayed-release pellets; loss or damage of pellets prevents using the dose. Swallow the Doryx/applesauce mixture immediately without chewing. Discard mixture if not used immediately.

Doryx MPC: Do not chew or crush tablets.

Parenteral: For IV use only; administer over 1 to 4 hours; avoid rapid infusion. Avoid extravasation (may be an irritant). Duration of IV therapy should be minimized, when possible, to avoid risk of thrombophlebitis.

Use: Labeled Indications

Acne vulgaris: Adjunctive therapy in severe acne.

Actinomycosis: Treatment of actinomycosis caused by Actinomyces israelii when penicillin is contraindicated.

Acute intestinal amebiasis: Adjunct to amebicides in acute intestinal amebiasis.

Anthrax, including inhalational anthrax (postexposure): Treatment of anthrax caused by Bacillus anthracis, including inhalational (postexposure) prophylaxis; to reduce the incidence or progression of disease following exposure to aerosolized B. anthracis.

Cholera: Treatment of cholera infections caused by Vibrio cholerae.

Clostridium: Treatment of infections caused by Clostridium spp. when penicillin is contraindicated.

Gram-negative infections: Treatment of infections caused by Escherichia coli, Klebsiella aerogenes (formerly Enterobacter aerogenes), Shigella spp., Acinetobacter spp., Klebsiella spp. (respiratory and urinary infections), and Bacteroides spp.; Neisseria meningitidis (when penicillin is contraindicated).

Gram-positive infections: Treatment of infections caused by Streptococcus spp., when susceptible.

Listeriosis: Treatment of listeriosis due to Listeria monocytogenes when penicillin is contraindicated.

Malaria, prophylaxis: Prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (under 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine-resistant strains.

Mycoplasma pneumoniae: Treatment of infections caused by Mycoplasma pneumoniae.

Ophthalmic infections: Treatment of inclusion conjunctivitis or trachoma caused by Chlamydia trachomatis.

Periodontitis (20 mg tablet and capsule [Periostat (Canadian product)] only): Adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis.

Relapsing fever: Treatment of relapsing fever caused by Borrelia recurrentis.

Respiratory tract infections: Treatment of respiratory infections caused by Haemophilus influenzae, Klebsiella spp., or Mycoplasma pneumoniae; treatment of upper respiratory tract infections caused by Streptococcus pneumoniae; respiratory infections caused by Staphylococcus aureus (doxycycline is not the drug of choice in the treatment of any type of staphylococcal infection).

Rickettsial infections: Treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever (Coxiella burnetii), rickettsialpox, and tick fevers caused by Rickettsiae.

Rosacea (Oracea, Apprilon [Canadian product] only): Treatment of inflammatory lesions (papules and pustules) of rosacea in adults.

Sexually transmitted infections: Treatment of lymphogranuloma venereum and uncomplicated urethral, endocervical, or rectal infections caused by Chlamydia trachomatis; granuloma inguinale (donovanosis) caused by Klebsiella granulomatis; chancroid caused by Haemophilus ducreyi; nongonococcal urethritis caused by Ureaplasma urealyticum; when penicillin is contraindicated, syphilis caused by Treponema pallidum.

Skin and soft tissue infections (Avidoxy only): Treatment of skin and soft tissue infections caused by S. aureus (doxycycline is not the drug of choice in the treatment of any type of staphylococcal infection).

Vincent infection: Treatment of Vincent infection caused by Fusobacterium fusiforme when penicillin is contraindicated.

Yaws: Treatment of yaws caused by Treponema pallidum subspecies pertenue when penicillin is contraindicated.

Zoonotic infections: Treatment of psittacosis (ornithosis) caused by Chlamydophila psittaci; plague due to Yersinia pestis; tularemia caused by Francisella tularensis; brucellosis caused by Brucella spp. (in conjunction with streptomycin); bartonellosis caused by Bartonella bacilliformis; infections caused by Campylobacter fetus.

Use: Off-Label: Adult

Anaplasmosis and ehrlichiosis; Bite wound infection (animal or human bite); Bullous pemphigoid; Chronic obstructive pulmonary disease, acute exacerbation; Empiric treatment (of sexually transmitted infections) following sexual assault; Endocarditis, prophylaxis before invasive dental procedures; Endocarditis, treatment, oral step-down therapy in patients who inject drugs; Epididymitis, acute; Hidradenitis suppurativa; Lyme disease (Borrelia spp. infection); Malaria, treatment; Otitis media, acute; Pelvic inflammatory disease; Pleurodesis, chemical (sclerosing agent for pleural effusion); Proctitis, acute or proctocolitis; Prosthetic joint infection; Sexually transmitted bacterial infections, postexposure prophylaxis; Surgical prophylaxis, uterine evacuation (induced abortion or pregnancy loss)

Medication Safety Issues
Sound-alike/look-alike issues:

Doxycycline may be confused with dicyclomine, doxepin, doxylamine

Doxy100 may be confused with Doxil

Monodox may be confused with Maalox

Oracea may be confused with Orencia

Vibramycin may be confused with vancomycin, Vibativ

International issues:

Oracea (US brand name) is marketed in Canada under the brand name Apprilon

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). Risk X: Avoid combination

Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). Risk C: Monitor therapy

Antacids: May decrease the absorption of Tetracyclines. Management: Separate administration of antacids and oral tetracycline derivatives by several hours when possible to minimize the extent of this potential interaction. Monitor for decreased therapeutic effects of tetracyclines. Risk D: Consider therapy modification

Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider therapy modification

Barbiturates: May decrease the serum concentration of Doxycycline. Risk C: Monitor therapy

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy

Bile Acid Sequestrants: May decrease the absorption of Tetracyclines. Risk C: Monitor therapy

Bismuth Subcitrate: May decrease the serum concentration of Tetracyclines. Management: Avoid administration of oral tetracyclines within 30 minutes of bismuth subcitrate administration. This is of questionable significance for at least some regimens intended to treat H. pylori infections. Risk D: Consider therapy modification

Bismuth Subsalicylate: May decrease the serum concentration of Tetracyclines. Management: Consider dosing tetracyclines 2 hours before or 6 hours after bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable. Risk D: Consider therapy modification

Calcium Salts: May decrease the serum concentration of Tetracyclines. Management: If coadministration of oral calcium with oral tetracyclines cannot be avoided, consider separating administration of each agent by several hours. Risk D: Consider therapy modification

CarBAMazepine: May decrease the serum concentration of Doxycycline. Risk C: Monitor therapy

Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid combination

Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics. Risk X: Avoid combination

Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). Risk X: Avoid combination

Fosphenytoin: May decrease the serum concentration of Doxycycline. Risk C: Monitor therapy

Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor therapy

Inhibitors of the Proton Pump (PPIs and PCABs): May decrease the bioavailability of Doxycycline. Risk C: Monitor therapy

Iron Preparations: Tetracyclines may decrease the absorption of Iron Preparations. Iron Preparations may decrease the serum concentration of Tetracyclines. Management: Avoid this combination if possible. Administer oral iron preparations at least 2 hours before, or 4 hours after, the dose of the oral tetracycline derivative. Monitor for decreased therapeutic effect of oral tetracycline derivatives. Risk D: Consider therapy modification

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Risk C: Monitor therapy

Lanthanum: May decrease the serum concentration of Tetracyclines. Management: Administer oral tetracycline antibiotics at least 2 hours before or after lanthanum. Risk D: Consider therapy modification

Lithium: Tetracyclines may increase the serum concentration of Lithium. Risk C: Monitor therapy

Magnesium Dimecrotate: May interact via an unknown mechanism with Tetracyclines. Risk C: Monitor therapy

Magnesium Salts: May decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent. Management: Avoid coadministration of oral magnesium salts and oral tetracyclines. If coadministration cannot be avoided, administer oral magnesium at least 2 hours before, or 4 hours after, oral tetracyclines. Monitor for decreased tetracycline therapeutic effects. Risk D: Consider therapy modification

Mecamylamine: Tetracyclines may enhance the neuromuscular-blocking effect of Mecamylamine. Risk X: Avoid combination

Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). Risk C: Monitor therapy

Methoxyflurane: Tetracyclines may enhance the nephrotoxic effect of Methoxyflurane. Risk X: Avoid combination

Mipomersen: Tetracyclines may enhance the hepatotoxic effect of Mipomersen. Risk C: Monitor therapy

Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Tetracyclines. Management: Avoid this combination if possible. If coadministration cannot be avoided, administer the polyvalent cation-containing multivitamin at least 2 hours before or 4 hours after the tetracycline derivative. Monitor for decreased tetracycline effects. Risk D: Consider therapy modification

Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Tetracyclines. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines cannot be avoided, administer the polyvalent cation-containing multivitamin either 2 hours before or 4 hours after the tetracycline product. Risk D: Consider therapy modification

Neuromuscular-Blocking Agents: Tetracyclines may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Penicillins: Tetracyclines may diminish the therapeutic effect of Penicillins. Risk C: Monitor therapy

Phenytoin: May decrease the serum concentration of Doxycycline. Risk C: Monitor therapy

Polyethylene Glycol-Electrolyte Solution: May decrease the absorption of Tetracyclines. Management: Give oral tetracyclines at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation. Risk D: Consider therapy modification

Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. Risk C: Monitor therapy

Quinapril: May decrease the serum concentration of Tetracyclines. Risk C: Monitor therapy

Retinoic Acid Derivatives: Tetracyclines may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern. Risk X: Avoid combination

RifAMPin: May decrease the serum concentration of Doxycycline. Risk C: Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification

Strontium Ranelate: May decrease the serum concentration of Tetracyclines. Management: In order to minimize any potential impact of strontium ranelate on tetracycline antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during tetracycline therapy. Risk X: Avoid combination

Sucralfate: May decrease the absorption of Tetracyclines. Management: Administer most tetracycline derivatives at least 2 hours prior to sucralfate in order to minimize the impact of this interaction. Administer oral omadacycline 4 hours prior to sucralfate. Risk D: Consider therapy modification

Sucroferric Oxyhydroxide: May decrease the serum concentration of Tetracyclines. Management: Administer oral/enteral doxycycline at least 1 hour before sucroferric oxyhydroxide. Specific dose separation guidelines for other tetracyclines are not presently available. No interaction is anticipated with parenteral administration of tetracyclines. Risk D: Consider therapy modification

Sulfonylureas: Tetracyclines may enhance the hypoglycemic effect of Sulfonylureas. Risk C: Monitor therapy

Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider therapy modification

Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. Risk C: Monitor therapy

Vitamin K Antagonists (eg, warfarin): Tetracyclines may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Food Interactions

Ethanol: Chronic ethanol ingestion may reduce the serum concentration of doxycycline.

Food: Doxycycline serum levels may be slightly decreased if taken with high-fat meal or milk. Administration with iron or calcium may decrease doxycycline absorption. May decrease absorption of calcium, iron, magnesium, zinc, and amino acids. Management: Administer Doryx and Doryx MPC without regard to meals. Administer Oracea and doxycycline 20 mg tablet on an empty stomach 1 hour before or 2 hours after meals.

Pregnancy Considerations

Tetracyclines cross the placenta (Mylonas 2011).

Therapeutic doses of doxycycline during pregnancy are unlikely to produce substantial teratogenic risk, but data are insufficient to say that there is no risk. In general, reports of exposure have been limited to short durations of therapy in the first trimester. Tetracyclines accumulate in developing teeth and long tubular bones (Mylonas 2011). Permanent discoloration of teeth (yellow, gray, brown) can occur following in utero exposure and is more likely to occur following long-term or repeated exposure.

Doxycycline is used for the treatment of Lyme disease. Vertical transmission from mother to fetus is not well documented; it is unclear if infection increases the risk of adverse pregnancy outcomes. A single prophylactic dose of doxycycline can be used in pregnant patients; the use of treatment doses should be individualized (IDSA/AAN/ACR [Lantos 2021]; Lambert 2020; SOGC [Smith 2020]).

Doxycycline is the recommended agent for the treatment of Rocky Mountain spotted fever (RMSF) in pregnant patients (CDC [Biggs 2016]).

Untreated plague (Yersinia pestis) infection in pregnant patients may result in hemorrhage (including postpartum hemorrhage), maternal and fetal death, preterm birth, and stillbirth. Limited data suggest maternal-fetal transmission of Y. pestis can occur if not treated. Pregnant patients should be treated for Y. pestis; parenteral antibiotics are preferred for initial treatment when otherwise appropriate. Doxycycline may be used as an alternative antibiotic for treating pregnant patients with bubonic, pharyngeal, pneumonic, or septicemic plague. Doxycycline may also be used as an alternative antibiotic for pre- and postexposure prophylaxis in pregnant patients exposed to Y. pestis (CDC [Nelson 2021]).

For other indications, many guidelines consider use of doxycycline to be contraindicated during pregnancy, or to be a relative contraindication in pregnant patients if other agents are available and appropriate for use (CDC [Anderson 2013]; CDC 2023b; HHS [OI adult] 2022; IDSA [Stevens 2014]). Doxycycline should not be used for the treatment of acne or rosacea in pregnant patients (AAD [Zaenglein 2016]). When systemic antibiotics are needed for dermatologic conditions, other agents are preferred (Kong 2013; Murase 2014). As a class, tetracyclines are generally considered second-line antibiotics in pregnant patients and their use should be avoided (Mylonas 2011).

Breastfeeding Considerations

Doxycycline is present in breast milk.

Concentrations of doxycycline in breast milk may increase with duration of therapy (Anderson 1991).

Oral absorption of doxycycline is not markedly influenced by simultaneous ingestion of milk; therefore, oral absorption of doxycycline by the breastfeeding infant would not be expected to be diminished by the calcium in the maternal milk.

The therapeutic use of doxycycline should be avoided during tooth development (children <8 years of age) unless there are no alternative therapies due to the potential for tissue hyperpigmentation, tooth enamel hypoplasia, or permanent tooth discoloration. Theoretically, this risk is also present in breastfeeding infants exposed to doxycycline via breast milk. Although breastfeeding is not specifically contraindicated, the effects of long-term exposure via breast milk are not known. The World Health Organization (WHO) states that maternal use of doxycycline should be avoided if possible but that a single dose or the short-term use of doxycycline is probably safe; there exists a possibility of dental staining and inhibition of bone growth in the infant, especially with prolonged use (WHO 2002). In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush and diarrhea (WHO 2002).

Current guidelines note that the short-term use of doxycycline for the treatment of RMSF is considered compatible with breastfeeding (CDC [Biggs 2016]). If used for the treatment or prophylaxis of malaria, breastfeeding during doxycycline therapy is considered compatible; however, the theoretical risk of dental staining and inhibition of long bone growth in the breastfeeding infant should be considered (WHO 2002). Breastfeeding is not recommended when doxycycline is being used for maternal treatment of acne (AAD [Zaenglein 2016]). According to the manufacturer, breastfeeding is not recommended during treatment for rosacea and for 5 days after the last doxycycline dose.

Dietary Considerations

Tetracyclines (in general): Take with food if gastric irritation occurs. While administration with food may decrease GI absorption of doxycycline by up to 20%, administration on an empty stomach is generally not recommended due to GI intolerance. Of currently available tetracyclines, doxycycline has the least affinity for calcium.

Doxycycline 20 mg tablet, Oracea, Apprilon [Canadian product]: Manufacturer states to take on an empty stomach 1 hour before or 2 hours after meals. Take with food if gastric irritation occurs.

Periostat [Canadian product]: Manufacturer states to take at least 1 hour before morning and evening meals. Take with food if gastric irritation occurs.

Some products may contain sodium.

Monitoring Parameters

CBC, renal and liver function tests periodically with prolonged therapy.

Patients with no risk factors for chronic Q fever should undergo clinical and serological evaluation 6 months after diagnosis of acute Q fever to identify possible progression to chronic disease. Postpartum women treated during pregnancy for acute Q fever, others who are at high risk for progression to chronic disease or when used as part of treatment for chronic Q fever infection unrelated to endocarditis or vascular infection (eg, osteoarticular infections or chronic hepatitis), assess serologic response at 3, 6, 12, 18, and 24 months after diagnosis of acute Q fever (or after delivery in pregnant women) (CDC [Anderson 2013]).

Mechanism of Action

Inhibits protein synthesis by binding with the 30S and possibly the 50S ribosomal subunit(s) of susceptible bacteria; may also cause alterations in the cytoplasmic membrane

20 mg tablets and capsules (Periostat [Canadian product]): Proposed mechanism: Has been shown to inhibit collagenase activity in vitro. Also has been noted to reduce elevated collagenase activity in the gingival crevicular fluid of patients with periodontal disease. Systemic levels do not reach inhibitory concentrations against bacteria.

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Oral: Almost completely absorbed from the GI tract; average peak plasma concentration may be reduced ~20% (30% for Doryx MPC) by high-fat meal or milk.

Distribution: Widely into body tissues and fluids including synovial, pleural, prostatic, seminal fluids, and bronchial secretions; saliva, aqueous humor, and CSF penetration is poor.

Vd: Infants, Children, and Adolescents: Median: 1.36 L/kg (range: 0.38 to 3.18 L/kg) (Thompson 2019).

Protein binding: >90%.

Metabolism: Not hepatic; partially inactivated in GI tract by chelate formation.

Bioavailability: Reduced at high pH; may be clinically significant in patients with gastrectomy, gastric bypass surgery or who are otherwise deemed achlorhydric.

Infants, Children, and Adolescents: 89.6% (Thompson 2019).

Half-life elimination:

Infants, Children, and Adolescents: Median: 18.8 hours (range: 4.8 to 41.3 hours) (Thompson 2019).

Adults: 18 to 22 hours.

Time to peak, serum: Oral: Immediate release: 1.5 to 4 hours; delayed release: 2.8 to 3 hours.

Excretion: Feces (30%); urine (23% to 40%).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: Excretion by the kidneys may fall as low as 1% to 5% in 72 hours in patients with CrCl <10 mL/minute.

Anti-infective considerations:

Parameters associated with efficacy: Time and concentration dependent, associated with 24-hour area under the curve (AUC24)/minimum inhibitory concentration (MIC); however, no specific goal AUC24/MIC has been identified (Agwuh 2006; Ambrose 2007; Cunha 2000; Smirnova 2011).

Expected drug exposure in normal renal function: AUC: Adults: Oral: 200 mg once daily for 1 dose, then 100 mg once daily: 12.7 ± 4.9 mg•hour/L (Schreiner 1985).

Postantibiotic effect: 0.7 to 2.8 hours, depending on organism (eg, S. aureus, S. pneumoniae, E. coli) (Cunha 2000).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (QA) Qatar: Doxydar | DuraDox | Farcodoxin | Monodoks | Tabocine | Unidox | Vibramycin
  1. Abramowicz M. Antimicrobial Prophylaxis in Surgery. Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy. 16th ed. Medical Letter; 2002.
  2. Achilles SL, Reeves MF; Society of Family Planning. Prevention of infection after induced abortion: release date October 2010: SFP guideline 20102. Contraception. 2011;83(4):295-309. doi:10.1016/j.contraception.2010.11.006 [PubMed 21397086]
  3. Acticlate (doxycycline hyclate) [prescribing information]. Malvern, PA: Almirall LLC; August 2021.
  4. Adoxa (doxycycline) [prescribing information]. Melville, NY: PharmaDerm; February 2012.
  5. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58(2):256-265. doi:10.1093/jac/dkl224 [PubMed 16816396]
  6. Ailani RK, Agastya G, Ailani RK, et al. Doxycycline is a Cost-Effective Therapy for Hospitalized Patients With Community-Acquired Pneumonia. Arch Intern Med. 1999;159(3):266-270. [PubMed 9989538]
  7. Akcam M, Artan R, Akcam FZ, Yilmaz A. Nail discoloration induced by doxycycline. Pediatr Infect Dis J. 2005;24(9):845-846. doi:10.1097/01.inf.0000177283.71692.56 [PubMed 16148859]
  8. Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol. 2008;47(3):284-288. doi:10.1111/j.1365-4632.2008.03445.x [PubMed 18289334]
  9. Alestig K. Studies on doxycycline during intravenous and oral treatment with reference to renal function. Scand J Infect Dis. 1973;5(3):193-198. doi:10.3109/inf.1973.5.issue-3.07 [PubMed 4767570]
  10. Al Rawahi Y, Dutt S. Doxycycline-induced oesophageal ulcer in a teenager: A case report. J Paediatr Child Health. 2019;55(12):1499-1500. doi:10.1111/jpc.14561 [PubMed 31290206]
  11. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis. 2007;44(1):79-86. doi:10.1086/510079 [PubMed 17143821]
  12. American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  13. American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021-2024 Report of the Committee on Infectious Diseases. 32nd ed. American Academy of Pediatrics; 2021.
  14. American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. American Academy of Pediatrics; 2018.
  15. American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 135: Second-trimester abortion. Obstet Gynecol. 2013;121(6):1394-1406. doi:10.1097/01.AOG.0000431056.79334.cc [PubMed 23812485]
  16. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins--Gynecology. ACOG Practice Bulletin No. 195: Prevention of infection after gynecologic procedures. Obstet Gynecol. 2018;131(6):e172-e1189. doi:10.1097/AOG.0000000000002670 [PubMed 29794678]
  17. Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group. MMWR Recomm Rep. 2013;62(RR-03):1-30. [PubMed 23535757]
  18. Anderson PO. Drug use during breast-feeding. Clin Pharm. 1991;10(8):594-624. [PubMed 1934918]
  19. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. [PubMed 27060684]
  20. Anon JB, Jacobs MR, Poole MD, et al; Sinus And Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg. 2004;130(1 suppl):1-45. doi:10.1016/j.otohns.2003.12.003 [PubMed 14726904]
  21. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196-204. doi:10.7326/0003-4819-106-2-196 [PubMed 3492164]
  22. Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2007;4(7):554-564. [PubMed 17878469]
  23. Apprilon (doxycycline) [product monograph]. Thornhill, Ontario, Canada: Galderma Canada Inc; May 2018.
  24. Ariza J, Bosilkovski M, Cascio A, et al; International Society of Chemotherapy; Institute of Continuing Medical Education of Ioannina. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med. 2007;4(12):e317. [PubMed 18162038]
  25. Atridox (doxycycline) controlled-release gel [product monograph]. Niagara on the Lake, Ontario, Canada: Henry Schein; June 2021.
  26. Azuma N, Hashimoto N, Nishioka A, Sano H. Black thyroid. Intern Med. 2010;49(16):1835-1836. doi:10.2169/internalmedicine.49.3528 [PubMed 20720371]
  27. Bachmann LH. Urethritis in adult men. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 26, 2021.
  28. Baddour LM, Chen AF. Prosthetic joint infection: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 31, 2022.
  29. Baddour LM, Harper M. Animal bites (dogs, cats, and other mammals): evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 24, 2024a.
  30. Baddour LM, Harper M. Human bites: Evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 24, 2024b.
  31. Baddour LM. Impetigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 22, 2021c.
  32. Baddour LM, Weimer MB, Wurcel AG, et al; American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Peripheral Vascular Disease. Management of infective endocarditis in people who inject drugs: a scientific statement from the American Heart Association. Circulation. 2022;146(14):e187-e201. doi:10.1161/CIR.0000000000001090 [PubMed 36043414]
  33. Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association (AHA). Circulation. 2015;132(15):1487-1515. [PubMed 26373317]
  34. Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis. 2015;61(6):e26-e46. [PubMed 26229122]
  35. Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis - United States. MMWR Recomm Rep. 2016;65(2):1-44. doi:10.15585/mmwr.rr6502a1 [PubMed 27172113]
  36. Björnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol. 2005;40(9):1095-1101. doi:10.1080/00365520510023846 [PubMed 16165719]
  37. Blakely KM, Drucker AM, Rosen CF. Drug-induced photosensitivity-An update: Culprit drugs, prevention and management. Drug Saf. 2019;42(7):827-847. doi:10.1007/s40264-019-00806-5 [PubMed 30888626]
  38. Böcker R, Mühlberg W, Platt D, et al. Serum Level, Half-Life and Apparent Volume of Distribution of Doxycycline in Geriatric Patients. Eur J Clin Pharmacol. 1986;30(1):105-108. [PubMed 3709622]
  39. Bonavina L, DeMeester TR, McChesney L, Schwizer W, Albertucci M, Bailey RT. Drug-induced esophageal strictures. Ann Surg. 1987;206(2):173-183. doi:10.1097/00000658-198708000-00010 [PubMed 3606243]
  40. Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022;36(10):1689-1704. doi:10.1111/jdv.18220 [PubMed 35766904]
  41. Bosilkovski M. Brucellosis: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 26, 2022.
  42. Bosilkovski M, Keramat F, Arapović J. The current therapeutical strategies in human brucellosis. Infection. 2021;49(5):823-832. doi:10.1007/s15010-021-01586-w [PubMed 33650077]
  43. Bossi P, Tegnell A, Baka A, et al; Taskforce on Bioterrorism (BICHAT), Public Health Directorate, European Commission, Luxembourg. Bichat guidelines for the clinical management of tularaemia and bioterrorism-related tularaemia. Euro Surveill. 2004;9(12):E9-E10. [PubMed 15677845]
  44. Bouferraa Y, Bou Zerdan M, Hamouche R, Azar E, Afif C, Jabbour R. Neurobrucellosis: brief review. Neurologist. 2021;26(6):248-252. doi:10.1097/NRL.0000000000000348 [PubMed 34734902]
  45. Bower WA, Schiffer J, Atmar RL, et al; CDC ACIP Anthrax Vaccine Work Group. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR Recomm Rep. 2019;68(4):1-14. doi:10.15585/mmwr.rr6804a1 [PubMed 31834290]
  46. Bradley JS, Byington CL, Shah SS, et al. The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):e25-e76. [PubMed 21880587]
  47. Bradley JS, Nelson JD, Kimberlin DK, et al, eds. Nelson's Pocket Book of Pediatric Antimicrobial Therapy. 28th ed. American Academy of Pediatrics; 2022.
  48. Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. Pediatrics. 2014;133(5):1411-1436. [PubMed 24777226]
  49. Brook I. Treatment of actinomycosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 26, 2022.
  50. Bryant SG, Fisher S, Kluge RM. Increased Frequency of Doxycycline Side Effects. Pharmacotherapy. 1987;7(4):125-129. [PubMed 3684731]
  51. Cac NN, Messingham MJ, Sniezek PJ, Walling HW. Stevens-Johnson syndrome induced by doxycycline. Cutis. 2007;79(2):119-122. [PubMed 17388211]
  52. Carroll LA, Laumann AE. Doxycycline-induced photo-onycholysis. J Drugs Dermatol. 2003;2(6):662-663. [PubMed 14711147]
  53. Centers for Disease Control and Prevention (CDC). Brucellosis: Assessing laboratory risk level and PEP. https://www.cdc.gov/brucellosis/laboratories/risk-level.html. Updated November 12, 2012. Accessed August 10, 2017.
  54. Centers for Disease Control and Prevention (CDC). Cholera - Vibrio cholerae infection. Antibiotic treatment: recommendations for the use of antibiotics for the treatment of cholera. https://www.cdc.gov/cholera/treatment/antibiotic-treatment.html. Updated June 1, 2022a. Accessed September 1, 2022.
  55. Centers for Disease Control and Prevention (CDC). Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever, Ehrlichioses, and Anaplasmosis - United States. MMWR Recomm Rep. 2006;55(RR-4):1-27. [PubMed 16572105]
  56. Centers for Disease Control and Prevention (CDC). Guidelines for the use of doxycycline post-exposure prophylaxis for bacterial sexually transmitted infection prevention. https://www.cdc.gov/std/treatment/guidelines-for-doxycycline.htm. Updated September 29, 2023a. Accessed October 4, 2023.
  57. Centers for Disease Control and Prevention (CDC). Treatment of malaria: guidelines for clinicians (United States). https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html. Updated June 28, 2023b. Accessed July 26, 2023.
  58. Centers for Disease Control and Prevention (CDC). Treatment of malaria: guidelines for clinicians (United States). https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html. Updated September 30, 2022b. Accessed January 7, 2023.
  59. Centers for Disease Control and Prevention (CDC). Q Fever - California, Georgia, Pennsylvania, and Tennessee, 2000-2001. MMWR Weekly. 2002;51(41):924-927. [PubMed 12403408]
  60. Centers for Disease Control and Prevention (CDC). Recommended antibiotic treatment for plague. 2015. https://www.cdc.gov/plague/healthcare/clinicians.html
  61. Centers for Disease Control and Prevention (CDC). Tickborne diseases of the United States: Tick bite prophylaxis. 2019. https://www.cdc.gov/ticks/tickbornediseases/tick-bite-prophylaxis.html.
  62. Centers for Disease Control and Prevention (CDC). Tularemia: for clinicians. https://www.cdc.gov/tularemia/clinicians/index.html. Updated July 5, 2022c. Accessed September 21, 2023.
  63. Centers for Disease Control and Prevention (CDC). Use of anthrax vaccine in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR. 2010;59(6):1-30. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5906a1.htm?s_cid=rr5906a1_e. [PubMed 20651644]
  64. Centers for Disease Control and Prevention (CDC). Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR. 2001;50(42):909-919. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5042a1.htm [PubMed 11699843]
  65. Centers for Disease Control and Prevention (CDC). Update: Investigation of Anthrax Associated with Intentional Exposure and Interim Public Health Guidelines, October 2001. MMWR Morb Mortal Wkly Rep. 2001;50(41):889-893. [PubMed 11686472]
  66. Cherry CC, Kersh GJ. Pediatric Q fever. Curr Infect Dis Rep. 2020;22(4):10.1007/s11908-020-0719-0. doi:10.1007/s11908-020-0719-0 [PubMed 34135692]
  67. Chow AW, Benninger MS, Brook I, et al; Infections Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012;54(8):e72-e112. [PubMed 22438350]
  68. Chung AM, Reed MD, Blumer JL. Antibiotics and Breast-Feeding: A Critical Review of the Literature. Paediatr Drugs. 2002;4(12):817-837. [PubMed 12431134]
  69. Cohlan SQ, Bevelander G, Tiamsic T. Growth inhibition of prematures receiving tetracycline. Am J Dis Child. 1963;453-461. [PubMed Cohlan.1963]
  70. Colmenero JD, Fernández-Gallardo LC, Agúndez JA, Sedeño J, Benítez J, Valverde E. Possible implications of doxycycline-rifampin interaction for treatment of brucellosis. Antimicrob Agents Chemother. 1994;38(12):2798-2802. [PubMed 7695265]
  71. Cone LA, Leung MM, Hirschberg J. Actinomyces odontolyticus bacteremia. Emerg Infect Dis. 2003;9(12):1629-1632. doi:10.3201/eid0912.020646 [PubMed 14720410]
  72. Cross R, Ling C, Day NP, McGready R, Paris DH. Revisiting doxycycline in pregnancy and early childhood – time to rebuild its reputation? Expert Opin Drug Saf. 2016;15(3):367-382. doi:10.1517/14740338.2016.1133584 [PubMed 26680308]
  73. Cunha BA, Domenico P, Cunha CB. Pharmacodynamics of doxycycline. Clin Microbiol Infect. 2000;6(5):270-273. doi:10.1046/j.1469-0691.2000.00058-2.x [PubMed 11168126]
  74. Daniels JM, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181(2):150-157. doi:10.1164/rccm.200906-0837OC [PubMed 19875685]
  75. Dattwyler RJ, Luft BJ, Kunkel MJ, et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med. 1997;337(5):289-94. doi:10.1056/NEJM199707313370501 [PubMed 9233865]
  76. Daunt N, Brodribb TR, Dickey JD. Oesophageal Ulceration Due to Doxycycline. Br J Radiol. 1985;58(696):1209-1211. [PubMed 3842633]
  77. Daya M, Nakamura Y. Pulmonary Disease From Biological Agents: Anthrax, Plague, Q Fever, and Tularemia. Crit Care Clin. 2005;21(4):747-763. [PubMed 16168313]
  78. De S, Chaudhuri A, Dutta P, Dutta D, De SP, Pal SC. Doxycycline in the treatment of cholera. Bull World Health Organ. 1976;54(2):177-179. [PubMed 1088099]
  79. Del Rosso JQ, Tanghetti E, Webster G, Stein Gold L, Thiboutot D, Gallo RL. Update on the management of rosacea from the American Acne & Rosacea Society (AARS). J Clin Aesthet Dermatol. 2020;13(6 suppl):S17-S24. [PubMed 33282106]
  80. Dennis DT, Inglesby TV, Henderson DA, et al; Working Group on Civilian Biodefense. Tularemia as a biological weapon: medical and public health management. JAMA. 2001;285(21):2763-2773. [PubMed 11386933]
  81. Deshpande A, Pasupuleti V, Thota P, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013;68(9):1951-1961. doi:10.1093/jac/dkt129 [PubMed 23620467]
  82. Doryx (doxycycline hyclate) [prescribing information]. Greenville, NC: Mayne Pharma; July 2022.
  83. Doryx MPC (doxycycline hyclate delayed release tablets) [prescribing information]. Raleigh, NC: Mayne Pharma; May 2023.
  84. Dowlati E, Dovico J, Unwin B. Skin hyperpigmentation and melanonychia from chronic doxycycline use. Ann Pharmacother. 2015;49(10):1175-1176. doi:10.1177/1060028015598166 [PubMed 26228938]
  85. Doxycycline capsules [prescribing information]. Congers, NY: Chartwell RX LLC; February 2022.
  86. Doxycycline hyclate capsules [product monograph]. Boucherville, Quebec, Canada: JAMP Pharma Corporation; July 2022.
  87. Doxycycline hyclate capsules, suspension, tablets, USP [prescribing information]. Congers, NY: Chartwell Rx LLC; February 2022.
  88. Doxycycline hyclate delayed-release tablets [prescribing information]. Greenville, NC: Mayne Pharma; February 2020.
  89. Doxycycline hyclate tablets, USP [prescribing information]. Philadelphia, PA: Lannett Company; May 2016.
  90. Doxycycline hyclate tablets, USP [prescribing information]. Congers, NY: Chartwell RX LLC; February 2023.
  91. Doxy 100 injection (doxycycline) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; February 2020.
  92. Doxy 100 injection (doxycycline) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; June 2020.
  93. Doxytab (doxycycline) [product monograph]. Laval, Quebec, Canada: Pro Doc Ltée: July 2019.
  94. Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013;13(1)(suppl 3):S163-186. [PubMed 23637225]
  95. Eyre RC. Evaluation of acute scrotal pain in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 6, 2021.
  96. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  97. Fenollar F, Fournier PE, Carrieri MP, et al. Risks Factors and Prevention of Q Fever Endocarditis. Clin Infect Dis. 2001;33(3):312-316. [PubMed 11438895]
  98. Fields JP. Bulging fontanel: a complication of tetracycline therapy in infants. J Pediatr. 1961;58:74-76. doi:10.1016/s0022-3476(61)80061-9 [PubMed 13699377]
  99. File TM. Treatment of community-acquired pneumonia in adults in the outpatient setting. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 31, 2022.
  100. Foucault C, Raoult D, Brouqui P. Randomized open trial of gentamicin and doxycycline for eradication of Bartonella quintana from blood in patients with chronic bacteremia. Antimicrob Agents Chemother. 2003;47(7):2204-2207. [PubMed 12821469]
  101. Francke EL, Neu HC. Chloramphenicol and Tetracyclines. Med Clin North Am. 1987;71(6):155-168. [PubMed 3320617]
  102. Friedman IS, Shelton RM, Phelps RG. Minocycline-induced hyperpigmentation of the tongue: successful treatment with the Q-switched ruby laser. Dermatol Surg. 2002;28(3):205-209. doi:10.1046/j.1524-4725.2002.01083.x [PubMed 11896769]
  103. Fronek L, Brazen B, Ross R, Miller R. Cervicofacial actinomycosis: a unique diagnostic challenge. Dermatol Online J. 2021;27(7). doi:10.5070/D327754367 [PubMed 34391332]
  104. Geisler WM, Koltun WD, Abdelsayed N, et al. Safety and efficacy of WC2031 versus vibramycin for the treatment of uncomplicated urogenital Chlamydia trachomatis infection: a randomized, double-blind, double-dummy, active-controlled, multicenter trial. Clin Infect Dis. 2012;55(1):82-88. [PubMed 22431798]
  105. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2022 report. https://goldcopd.org/2023-gold-report-2/. Updated 2023. Accessed January 30, 2023.
  106. Global Task Force on Cholera Control (GTFCC). Cholera outbreak response field manual. https://www.gtfcc.org/wp-content/uploads/2020/04/gtfcc-cholera-outbreak-response-field-manual.pdf. Published October 2019. Accessed September 1, 2022.
  107. Goetze S, Hiernickel C, Elsner P. Phototoxicity of doxycycline: A systematic review on clinical manifestations, frequency, cofactors, and prevention. Skin Pharmacol Physiol. 2017;30(2):76-80. doi:10.1159/000458761. [PubMed 28291967]
  108. Golub LM, Elburki MS, Walker C, et al. Non-antibacterial tetracycline formulations: host-modulators in the treatment of periodontitis and relevant systemic diseases. Int Dent J. 2016;66(3):127-135. doi:10.1111/idj.12221 [PubMed 27009489]
  109. Gould FK, Denning DW, Elliott TS, et al. Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother. 2012;67(2):269-289. [PubMed 22086858]
  110. Graber E. Acne vulgaris: Management of moderate to severe acne in adolescents and adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 3, 2022.
  111. Guo Y, Li HM, Li CX, Zhu WQ, Wang YF, He YH. Oesophageal ulceration in adult patients treated with doxycycline for acne vulgaris. J Int Med Res. 2019;47(12):6404-6409. doi:10.1177/0300060519881272 [PubMed 31709872]
  112. Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016;164(6):425-434. doi:10.7326/M15-1840 [PubMed 26785402]
  113. Hartzell JD, Wood-Morris RN, Martinez LJ, et al. Q Fever: Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc. 2008;83(5):574-579. [PubMed 18452690]
  114. Hasanjani Roushan MR, Mohraz M, Hajiahmadi M, Ramzani A, Valayati AA. Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans. Clin Infect Dis. 2006;42(8):1075-1080. [PubMed 16575723]
  115. Haskes C, Shea M, Imondi D. Minocycline-induced scleral and dermal hyperpigmentation. Optom Vis Sci. 2017;94(3):436-442. doi:10.1097/OPX.0000000000001024 [PubMed 27870777]
  116. Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. J Clin Pharm Ther. 2007;32(5):483-487. doi:10.1111/j.1365-2710.2007.00853.x [PubMed 17875115]
  117. Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy. 2009;29(5):562-577. doi:10.1592/phco.29.5.562 [PubMed 19397464]
  118. Hendricks KA, Wright ME, Shadomy SV, et al; Workgroup on Anthrax Clinical Guidelines. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014;20(2):e130687. doi:10.3201/eid2002.130687 [PubMed 24447897]
  119. HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new. Updated March 1, 2016. Accessed July 30, 2017.
  120. Hicks CB, Clement M. Syphilis: treatment and monitoring. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 31, 2022.
  121. Houin G, Brunner F, Nebout T, Cherfaoui M, Lagrue G, Tillement JP. The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man. Br J Clin Pharmacol. 1983;16(3):245-252. doi:10.1111/j.1365-2125.1983.tb02157.x [PubMed 6626415]
  122. Hsu K. Treatment of Chlamydia trachomatis infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2022.
  123. Hu L. Treatment of Lyme disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 29, 2021.
  124. Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a Biological Weapon: Medical and Public Health Management. Working Group on Civilian Biodefense. JAMA. 2000;283(17):2281-2290. [PubMed 10807389]
  125. Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a Biological Weapon: Medical and Public Health Management. Working Group on Civilian Biodefense. JAMA. 1999;281(18):1735-1745. [PubMed 10328075]
  126. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. [PubMed 10891521]
  127. Jia B, Zhang F, Pang P, et al. Brucella endocarditis: Clinical features and treatment outcomes of 10 cases from Xinjiang, China. J Infect. 2017;74(5):512-514. doi:10.1016/j.jinf.2017.01.011 [PubMed 28143754]
  128. Jolkovsky DL, Ciancio S. Chemotherapeutic Agents. In: Newman MG, Takei HH, Klokkevold PR, et al, eds. Clinical Periodontology. 10th ed. Saunders/Elsevier; 2006:802-803.
  129. Johnston S. Feeling blue? Minocycline-induced staining of the teeth, oral mucosa, sclerae and ears - a case report. Br Dent J. 2013;215(2):71-73. doi:10.1038/sj.bdj.2013.682 [PubMed 23887527]
  130. Jørgensen AR, Yao Y, Thomsen SF, Ring HC. Treatment of hidradenitis suppurativa with tetracycline, doxycycline, or lymecycline: a prospective study. Int J Dermatol. 2021;60(7):785-791. doi:10.1111/ijd.15459 [PubMed 33660281]
  131. Joshi N, Miller DQ. Doxycycline Revisited. Arch Intern Med. 1997;157(13):1421-1428. [PubMed 9224219]
  132. Keijmel SP, van Kasteren ME, Blokx WA, van der Meer JW, van Rossum M, Bleeker-Rovers CP. Cutaneous hyperpigmentation induced by doxycycline: a case series. Neth J Med. 2015;73(1):37-40. [PubMed 26219940]
  133. Kim SH, Jeon JB, Kim JW, et al. Clinical and endoscopic characteristics of drug-induced esophagitis. World J Gastroenterol. 2014;20(31)10994-10999.
  134. Kong YL, Tey HL. Treatment of acne vulgaris during pregnancy and lactation. Drugs. 2013;73(8):779-787. [PubMed 23657872]
  135. Kvale PA, Selecky, Prakash BS, et al. Palliative Care In Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). Chest. 2007;132(suppl 3):268S-403S. doi:10.1378/chest.07-1391 [PubMed 17873181]
  136. Lambert JS. An overview of tickborne infections in pregnancy and outcomes in the newborn: the need for prospective studies. Front Med (Lausanne). 2020;7:72. doi:10.3389/fmed.2020.00072 [PubMed 32211414]
  137. Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis, and treatment of lyme disease. Arthritis Care Res (Hoboken). 2021;73(1):1-9. doi:10.1002/acr.24495 [PubMed 33251700]
  138. Lasser AE, Steiner MM. Tetracycline photo-onycholysis. Pediatrics. 1978;61(1):98-99. [PubMed 263881]
  139. Layton AM, Cunliffe WJ. Phototoxic eruptions due to doxycycline--a dose-related phenomenon. Clin Exp Dermatol. 1993;18(5):425-427. doi:10.1111/j.1365-2230.1993.tb02242.x [PubMed 8252763]
  140. Lebrun-Vignes B, Kreft-Jais C, Castot A, Chosidow O; French Network of Regional Centers of Pharmacovigilance. Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature. Br J Dermatol. 2012;166(6):1333-1341. doi:10.1111/j.1365-2133.2012.10845.x [PubMed 22283782]
  141. Lee P, Crutch ER, Morrison RB. Doxycycline: studies in normal subjects and patients with renal failure. N Z Med J. 1972;75(481):355-358. [PubMed 4564509]
  142. Letteri JM, Miraflor F, Tablante V, Siddiqi S. Doxycycline (Vibramycin) in chronic renal failure. Nephron. 1973;11(5):318-324. [PubMed 4584946]
  143. Li WQ, Drucker AM, Cho E, et al. Tetracycline use and risk of incident skin cancer: a prospective study. Br J Cancer. 2018;118(2):294-298. doi:10.1038/bjc.2017.378 [PubMed 29073637]
  144. Limb CJ, Lustig LR, Durand ML. Acute otitis media in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 27, 2022.
  145. Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections. Clin Infect Dis. 2012;54(12):e132-e173. [PubMed 22619242]
  146. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285-292. [PubMed 21217178]
  147. Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of Antimicrobial Agents in the Elderly. Rev Infect Dis. 1987;9(2):250-264. [PubMed 3296097]
  148. Lochary ME, Lockhart PB, Williams WT Jr. Doxycycline and staining of permanent teeth. Pediatr Infect Dis J. 1998;17(5):429-431. doi:10.1097/00006454-199805000-00019 [PubMed 9613662]
  149. Luetkemeyer AF, Donnell D, Dombrowski JC, et al; DoxyPEP Study Team. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med. 2023;388(14):1296-1306. doi:10.1056/NEJMoa2211934 [PubMed 37018493]
  150. Maier LE. Management of rosacea. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 26, 2022.
  151. McClain MT. Treatment of Rocky Mountain spotted fever. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 6, 2022.
  152. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Resp Crit Care Med. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST [PubMed 31573350]
  153. Million M, Walter G, Thuny F, Habib G, Raoult D. Evolution from acute Q fever to endocarditis is associated with underlying valvulopathy and age and can be prevented by prolonged antibiotic treatment. Clin Infect Dis. 2013;57(6):836-844. doi:10.1093/cid/cit419 [PubMed 23794723]
  154. Molina JM, Charreau I, Chidiac C, et al; ANRS IPERGAY Study Group. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018;18(3):308-317. doi:10.1016/S1473-3099(17)30725-9 [PubMed 29229440]
  155. Monodoxyne NL (doxycycline) [prescribing information]. Petaluma, CA: IntraDerm Pharmaceuticals; November 2015.
  156. Moore A, Ling M, Bucko A, Manna V, Rueda MJ. Efficacy and safety of subantimicrobial dose, modified-release doxycycline 40 mg versus doxycycline 100 mg versus placebo for the treatment of inflammatory lesions in moderate and severe acne: a randomized, double-blinded, controlled study. J Drugs Dermatol. 2015;14(6):581-586. [PubMed 26091383]
  157. Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. J Am Acad Dermatol. 2014;70(3):e1-14. [PubMed 24528911]
  158. Murrell DF, Ramirez-Quizon M. Management and prognosis of bullous pemphigoid. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 24, 2023.
  159. Mylonas I. Antibiotic Chemotherapy During Pregnancy and Lactation Period: Aspects for Consideration. Arch Gynecol Obstet. 2011;283(1):7-18. [PubMed 20814687]
  160. Nadelman RB, Nowakowski J, Fish D, et al; Tick Bite Study Group. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med. 2001;345(2):79-84. doi:10.1056/NEJM200107123450201 [PubMed 11450675]
  161. Nelson CA, Meaney-Delman D, Fleck-Derderian S, Cooley KM, Yu PA, Mead PS; contributors. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response. MMWR Recomm Rep. 2021;70(3):1-27. doi:10.15585/mmwr.rr7003a1 [PubMed 34264565]
  162. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70(2):252-289. doi:10.1016/j.jacc.2017.03.011 [PubMed 28315732]
  163. Olson JM, Vary JC Jr. Primary cutaneous Actinomyces neuii infection of the breast successfully treated with doxycycline. Cutis. 2013;92(6):E3-E4. [PubMed 24416755]
  164. Opfer K. The bulging fontanelle. Lancet. 1963;1(7272):116. doi:10.1016/s0140-6736(63)91135-8 [PubMed 13940207]
  165. Oracea (doxycycline) [prescribing information]. Fort Worth, TX: Galderma Laboratories LP; December 2021.
  166. Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(1):e1-e25. [PubMed 23223583]
  167. Pazzaglia M, Venturi M, Tosti A. Photo-onycholysis caused by an unusual beach game activity: a pediatric case of a side effect caused by doxycycline. Pediatr Dermatol. 2014;31(1):e26-e27. doi:10.1111/pde.12223 [PubMed 24015834]
  168. Pepine M, Flowers FP, Ramos-Caro FA. Extensive cutaneous hyperpigmentation caused by minocycline. J Am Acad Dermatol. 1993;28(2 Pt 2):292-295. doi:10.1016/0190-9622(93)70037-t [PubMed 8436641]
  169. Periostat (doxycycline hyclate capsules, USP 20 mg) [product monograph]. Montreal, Quebec, Canada: PENDOPHARM; November 2018.
  170. Porcel JM, Salud A, Nabal M, et al. Rapid Pleurodesis With Doxycycline Through a Small-Bore Catheter for the Treatment of Metastatic Malignant Effusions. Support Care Cancer. 2006;14(5):475-478. [PubMed 16404570]
  171. Powell AM, Nyirjesy P. Acute cervicitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 26, 2021.
  172. Pöyhönen H, Nurmi M, Peltola V, Alaluusua S, Ruuskanen O, Lähdesmäki T. Dental staining after doxycycline use in children. J Antimicrob Chemother. 2017;72:2887-2890. doi:10.1093/jac/dkx245
  173. Raeder JC. Anaphylactoid reaction caused by intravenous doxycycline during general anesthesia and beta-blockade treatment. Drug Intell Clin Pharm. 1984;18(6):481-482. doi:10.1177/106002808401800606 [PubMed 6145571]
  174. Rams TE, Slots J. Antibiotics in Periodontal Therapy: An Update. Compendium. 1992;13(12):1130, 1132, 1134. [PubMed 1298559]
  175. Refer to manufacturer's labeling.
  176. Robinson LA, Fleming WH, Galbraith TA. Intrapleural doxycycline control of malignant pleural effusions. Ann Thorac Surg. 1993;55(5):1115-1121; discussion 1121-1122. [PubMed 8494419]
  177. Rojas-Moreno C, Bhartee H, Vasudevan A, Adiga R, Salzer W. Tetracyclines for treatment of tularemia: a case series. Open Forum Infect Dis. 2018;5(9):ofy176. doi:10.1093/ofid/ofy176 [PubMed 30191155]
  178. Rolain JM, Brouqui P, Koehler JE, Maguina C, Dolan MJ, Raoult D. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother. 2004;48(6):1921-1933. [PubMed 15155180]
  179. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015;152(2 suppl):S1-S39. doi:10.1177/0194599815572097 [PubMed 25832968]
  180. Ross J, Judlin P, Nilas L. European Guideline for the Management of Pelvic Inflammatory Disease. Int J STD AIDS. 2007;18(10):662-666. http://std.sagepub.com/content/18/10/662.full.pdf+html. Accessed May 15, 2013. [PubMed 17945043]
  181. Royal College of Obstetricians and Gynaecologists (RCOG). Best practice in comprehensive abortion care. Best Practice Paper No. 2 https://www.rcog.org.uk/en/guidelines-research-services/guidelines/bpp2/. June 2015.
  182. Sachs N, Atiya-Nasagi Y, Beth-Din A, et al. Chronic Q fever infections in Israeli children: a 25-year nationwide study. Pediatr Infect Dis J. 2018;37(3):212-217. doi:10.1097/INF.0000000000001790 [PubMed 28938256]
  183. Sack DA, Islam S, Rabbani H, Islam A. Single-dose doxycycline for cholera. Antimicrob Agents Chemother. 1978;14(3):462-464. doi:10.1128/AAC.14.3.462 [PubMed 708024]
  184. Saivin S, Hovin G. Clinical Pharmacokinetics of Doxycycline and Minocycline. Clin Pharmacokinet. 1985;15:355-366. [PubMed 3072140]
  185. Sanchez J, Somolinos AL, Almodóvar PI, Webster G, Bradshaw M, Powala C. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol. 2005;53(5):791-797. [PubMed 16243127]
  186. Schreiner A, Digranes A. Pharmacokinetics of lymecycline and doxycycline in serum and suction blister fluid. Chemotherapy. 1985;31(4):261-265. doi:10.1159/000238345 [PubMed 4028871]
  187. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22):2355-2365. doi:10.1056/NEJMra0800353 [PubMed 19038881]
  188. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol. 1997;133(10):1224-1230. [PubMed 9382560]
  189. Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10(2):256-259. [PubMed 19188870]
  190. Sherman S, Ravikrishnan KP, Patel AS, Seidman JC. Optimum anesthesia with intrapleural lidocaine during chemical pleurodesis with tetracycline. Chest. 1988;93(3):533-536. doi:10.1378/chest.93.3.533 [PubMed 3342661]
  191. Shute L, Walkty A, Embil JM. Minocycline-induced cutaneous hyperpigmentation. CMAJ. 2020;192(34):E981. doi:10.1503/cmaj.200012 [PubMed 32839167]
  192. Simoff MJ, Lally B, Slade MG, et al. Symptom management in patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 suppl):e455S-e497S. doi:10.1378/chest.12-2366 [PubMed 23649452]
  193. Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, Paul M. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. BMJ. 2008;336(7646):701-704. doi:10.1136/bmj.39497.500903.25 [PubMed 18321957]
  194. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139(4):459-464. [PubMed 12707093]
  195. Smilack JD, Wilson WR, Cockerill FR 3rd. Tetracyclines, Chloramphenicol, Erythromycin, Clindamycin, and Metronidazole. Mayo Clin Proc. 1991;66(12):1270-1280. [PubMed 1749296]
  196. Smiley CJ, Tracy SL, Abt E, et al. Evidence-based clinical practice guideline on the nonsurgical treatment of chronic periodontitis by means of scaling and root planing with or without adjuncts. J Am Dent Assoc. 2015;146(7):525-535. doi:10.1016/j.adaj.2015.01.026 [PubMed 26113100]
  197. Smirnova MV, Strukova EN, Portnoy YA, et al. The antistaphylococcal pharmacodynamics of linezolid alone and in combination with doxycycline in an in vitro dynamic model. J Chemother. 2011;23(3):140-144. doi:10.1179/joc.2011.23.3.140 [PubMed 21742582]
  198. Smith GN, Moore KM, Hatchette TF, Nicholson J, Bowie W, Langley JM. Committee Opinion No. 399: Management of tick bites and Lyme disease during pregnancy. J Obstet Gynaecol Can. 2020;42(5):644-653. doi:10.1016/j.jogc.2020.01.001 [PubMed 32414479]
  199. Spach DH. Bartonella infections in people with HIV. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 2, 2022c.
  200. Spach DH. Clinical features, diagnosis, and treatment of Bartonella quintana infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 2, 2022a.
  201. Spach DH. Endocarditis caused by Bartonella. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 25, 2022b.
  202. Spelman D, Baddour LM. Skin abscesses in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 24, 2023a.
  203. Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 24, 2023b.
  204. St. Cyr S, Barbee L, Workowski KA, et al. Update to CDC's treatment guidelines for gonococcal infection, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1911-1916. doi:10.15585/mmwr.mm6950a6 [PubMed 33332296]
  205. Steadman W, Brown Z, Wall CJ. Minocycline black bone disease in arthroplasty: a systematic review. J Orthop Surg Res. 2021;16(1):479. doi:10.1186/s13018-021-02617-w. Erratum in: J Orthop Surg Res. 2022;17(1):295. [PubMed 34348742]
  206. Stern EJ, Uhde KB, Shadomy SV, et al. Conference Report on Public Health and Clinical Guidelines for Anthrax. Emerg Infect Dis. 2008;14(4). http://wwwnc.cdc.gov/eid/article/14/4/07-0969.htm. [PubMed 18394267]
  207. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):147-159. doi:10.1093/cid/ciu296 [PubMed 24947530]
  208. Stout J. Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 21, 2022.
  209. Stultz JS, Eiland LS. Doxycycline and tooth discoloration in children: changing of recommendations based on evidence of safety. Ann Pharmacother. 2019;53(11):1162-1166. doi:10.1177/1060028019863796 [PubMed 31280586]
  210. Stupica D, Lusa L, Ruzić-Sabljić E, Cerar T, Strle F. Treatment of erythema migrans with doxycycline for 10 days versus 15 days. Clin Infect Dis. 2012;55(3):343-350. doi:10.1093/cid/cis402 [PubMed 22523260]
  211. Tan KR, Arguin PM. Travel-related infectious diseases: Malaria. In: CDC Yellow Book 2020: Health Information for International Travel. Centers for Disease Control and Prevention (CDC). https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/malaria. Last reviewed July 1, 2019. Accessed April 24, 2020.
  212. Targadox (doxycycline) [prescribing information]. Scottsdale, AZ: Journey Medical Corporation; January 2019.
  213. Tariq R, Cho J, Kapoor S, et al. Low risk of primary Clostridium difficile infection with tetracyclines: A systematic review and metaanalysis. Clin Infect Dis. 2018;66(4):514-522. doi:10.1093/cid/cix833 [PubMed 29401273]
  214. Thompson EJ, Wu H, Melloni C, et al. Population pharmacokinetics of doxycycline in children. Antimicrob Agents Chemother. Published online September 23, 2019. doi:10.1128/AAC.01508-19 [PubMed 31548185]
  215. Todd SR, Dahlgren FS, Traeger MS, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever. J Pediatr. 2015;166(5):1246-1251. [PubMed 25794784]
  216. Tsentemeidou A, Sotiriou E, Vakirlis E, Sideris N, Lallas A, Ioannides D. Treatment strategies for hidradenitis suppurativa: real-life data from a tertiary Greek hospital. Arch Dermatol Res. 2022;314(3):301-305. doi:10.1007/s00403-020-02150-6 [PubMed 33094412]
  217. US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf. Updated September 28, 2022. Accessed November 17, 2022.
  218. Vibramycin (doxycycline oral) [prescribing information]. New York; NY: Pfizer; received August 2017.
  219. Vibramycin (doxycycline injection) [prescribing information]. New York; NY: Pfizer; July 2017.
  220. Vibramycin Capsules (doxycycline) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; December 2015.
  221. Vibramycin Calcium Syrup (doxycycline calcium) [prescribing information]. New York; NY: Pfizer Labs; December 2019.
  222. Vibramycin Hyclate Capsules (doxycycline hyclate) [prescribing information]. New York; NY: Pfizer Labs; December 2019.
  223. Vibramycin Monohydrate for Oral Suspension (doxycycline monohydrate) [prescribing information]. New York; NY: Pfizer Labs; December 2019.
  224. Vibra-Tabs Film Coated Tablets (doxycycline hyclate) [prescribing information]. New York; NY: Pfizer Labs; December 2019.
  225. Vural S, Gündoğdu M, Akay BN, et al. Hidradenitis suppurativa: Clinical characteristics and determinants of treatment efficacy. Dermatol Ther. 2019;32(5):e13003. doi:10.1111/dth.13003 [PubMed 31237104]
  226. White KO, Jones HE, Shorter J, et al. Second-trimester surgical abortion practices in the United States. Contraception. 2018:S0010-7824(18)30140-9. doi:10.1016/j.contraception.2018.04.004 [PubMed 29665357]
  227. White KO, Jones HE, Lavelanet A, et al. First-trimester aspiration abortion practices: a survey of United States abortion providers. Contraception. 2019;99(1):10-15. doi:10.1016/j.contraception.2018.08.011 [PubMed 30125557]
  228. Wilcox CM. Evaluation of anorectal symptoms in men who have sex with men. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 31, 2022.
  229. Wildenthal JA, Atkinson A, Lewis S, et al. Outcomes of partial oral antibiotic treatment for complicated Staphylococcus aureus bacteremia in people who inject drugs. Clin Infect Dis. 2023;76(3):487-496. doi:10.1093/cid/ciac714 [PubMed 36052413]
  230. Williams HC, Wojnarowska F, Kirtschig G, et al; UK Dermatology Clinical Trials Network BLISTER Study Group. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet. 2017;389(10079):1630-1638. doi:10.1016/S0140-6736(17)30560-3 [PubMed 28279484]
  231. Williams PCM, Berkley JA. Guidelines for the management of paediatric cholera infection: a systematic review of the evidence. Paediatr Int Child Health. 2018;38(Supp 1):S16-S31. doi:10.1080/20469047.2017.1409452 [PubMed 29790841]
  232. Wilson KH. Prevention of anthrax. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 21, 2023.
  233. Wilson WR, Cockerill FR 3rd. Tetracyclines, Chloramphenicol, Erythromycin, and Clindamycin. Mayo Clin Proc. 1987;62(10):906-915. [PubMed 3657308]
  234. Wilson WR, Gewitz M, Lockhart PB, et al; American Heart Association Young Hearts Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and the Council on Quality of Care and Outcomes Research. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. Circulation. 2021;143(20):e963-e978. doi:10.1161/CIR.0000000000000969 [PubMed 33853363]
  235. Wilson W, Taubert KA, Gewitz M,et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116(15):1736-1754. doi:10.1161/CIRCULATIONAHA.106.183095 [PubMed 17446442]
  236. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1 [PubMed 34292926]
  237. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1-137. [PubMed 26042815]
  238. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. https://apps.who.int/iris/handle/10665/62435. Published 2002.
  239. World Health Organization. Brucellosis in humans and animals. 2006. http://www.who.int/csr/resources/publications/Brucellosis.pdf.
  240. World Health Organization (WHO) Global Task Force on Cholera Control. First steps for managing an outbreak of acute diarrhoea. http://www.who.int/cholera/publications/firststeps/en/. Updated November 2010. Accessed July 25, 2013.
  241. World Health Organization (WHO). WHO guidelines for malaria (2023). https://www.who.int/publications/i/item/guidelines-for-malaria. Published March 14, 2023. Accessed July 20, 2023.
  242. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(9):1089-1134. doi:10.1086/508667 [PubMed 17029130]
  243. Wormser GP, Ramanathan R, Nowakowski J, et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138(9):697-704. [PubMed 12729423]
  244. Wormser GP, Wormser RP, Strle F, Myers R, Cunha BA. How safe is doxycycline for young children or for pregnant or breastfeeding women? Diagn Microbiol Infect Dis. 2019;93(3):238-242. doi:10.1016/j.diagmicrobio.2018.09.015 [PubMed 30442509]
  245. Wyler DJ. Malaria: Overview and Update. Clin Infect Dis. 1993;16(4):449-456. [PubMed 8513046]
  246. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33. http://www.jaad.org/article/S0190-9622(15)02614-6/pdf. [PubMed 26897386]
  247. Zakhem GA, Motosko CC, Mu EW, Ho RS. Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: A systematic review. J Am Acad Dermatol. 2019;80(4):957-969. doi:10.1016/j.jaad.2018.09.031 [PubMed 30287313]
  248. Zheng N, Wang W, Zhang JT, et al. Neurobrucellosis. Int J Neurosci. 2018;128(1):55-62. doi:10.1080/00207454.2017.1363747 [PubMed 28768443]
Topic 9393 Version 924.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟